<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2004200059
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VITRAKVI
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LAROTRECTINIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        26100.26
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Penn Pharmaceutical Services Ltd" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Penn Pharmaceutical Services Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2947]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Bayer Saudi Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BAYER AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What VITRAKVI is used for</strong></p><p>VITRAKVI contains the active substance larotrectinib.</p><p>It is used in adults, adolescents and children to treat solid tumours (cancer) in various parts of the body that are caused by a change in the NTRK gene (neurotrophic tyrosine receptor kinase).</p><p>VITRAKVI is only used when</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->these cancers are advanced or have spread to other parts of the body or if a surgery to remove the cancer is likely to cause severe complications <strong>and</strong></p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->there are no satisfactory treatment options.</p><p>Before you are given VITRAKVI, your doctor will do a test to check if you have the change in the NTRK gene.</p><p><strong>How VITRAKVI works</strong></p><p>In patients whose cancer is due to an altered NTRK gene, the change in the gene causes the body to make an abnormal protein called TRK fusion protein, which can lead to uncontrolled cell growth and cancer. VITRAKVI blocks the action of TRK fusion proteins and so may slow or stop the growth of the cancer. It may also help to shrink the cancer.</p><p>If you have any questions on how VITRAKVI works or why it has been prescribed for you, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take VITRAKVI if</strong></p><p>you are allergic to larotrectinib or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p><strong>Tests and checks</strong></p><p>VITRAKVI can increase the amount of the liver enzymes ALT and AST in your blood. Your doctor will do blood tests before and during treatment to check the level of ALT and AST and check how well your liver is working.</p><p>Other medicines and VITRAKVI</p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. This is because some medicines may affect the way VITRAKVI works or VITRAKVI may affect how other medicines work.</p><p>In particular, tell your doctor, pharmacist or nurse if you are taking any of the following medicines:</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->medicines used to treat fungal or bacterial infections called itraconazole, voriconazole, clarithromycin, telithromycin, troleandomycin</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->a medicine used to treat Cushing&rsquo;s syndrome called ketoconazole</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->medicines used to treat HIV infection called atazanavir, indinavir, nelfinavir, ritonavir, saquinavir, rifabutin, efavirenz</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->a medicine used to treat depression called nefazodone</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->medicines used to treat epilepsy called phenytoin, carbamazepine, phenobarbital</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->a herbal medicine used to treat depression called St. John&rsquo;s wort</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->a medicine used to treat tuberculosis called rifampicin</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->a medicine used for strong pain relief called alfentanil</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->medicines used to prevent organ rejection after an organ transplant called ciclosporin, sirolimus, tacrolimus</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->a medicine used to treat an abnormal heart rhythm called quinidine</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->medicines used to treat migraines called dihydroergotamine, ergotamine</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->a medicine used to treat long‑term pain called fentanyl</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->a medicine used to control involuntary movements or sounds called pimozide</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->a medicine to help you stop smoking called bupropion</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->medicines to reduce blood sugar levels called repaglinide, tolbutamide</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->a medicine that prevents blood clots called warfarin</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->a medicine used to reduce the amount of acid produced in the stomach called omeprazole</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->a medicine used to help control high blood pressure called valsartan</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->a group of medicines used to help lower cholesterol called statins</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->hormonal medicines used for contraception, see section &ldquo;contraception &ndash; for men and women&rdquo; below.</p><p>If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse.</p><p>Taking VITRAKVI with food and drink</p><p>Do not eat grapefruit or drink grapefruit juice while taking VITRAKVI. This is because it may increase the amount of VITRAKVI in your body.</p><p>Pregnancy and breast‑feeding</p><p><u>Pregnancy</u></p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>You should not use VITRAKVI during pregnancy since the effect of VITRAKVI on the unborn is not known.</p><p><u>Breast‑feeding</u></p><p>Do not breast‑feed while taking this medicine and for 3&nbsp;days after the last dose. This is because it is not known if VITRAKVI passes into breast milk.</p><p>Contraception &ndash; for men and women</p><p>You should avoid getting pregnant while taking this medicine.</p><p>If you are able to become pregnant, your doctor should do a pregnancy test before you start treatment.</p><p>You must use effective methods of contraception while taking VITRAKVI and for at least 1&nbsp;month after the last dose, if</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->you are able to become pregnant. If you use hormonal contraceptives, you should also use a barrier method, such as a condom.</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->you have sex with a woman able to become pregnant.</p><p>Ask your doctor about the best method of contraception for you.</p><p>Driving, cycling and using machines</p><p>VITRAKVI may make you feel dizzy or tired. If this happens, do not drive, cycle or use any tools or machines.</p><p>VITRAKVI contains:</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]--><strong>sucrose</strong>: it may be harmful to the teeth. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->22 mg <strong>sorbitol </strong>in 1 mL. Sorbitol is a source of fructose. If your doctor has told you that you or your child have an intolerance to some sugars or if you have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in which a person cannot break down fructose, talk to your doctor before you or your child take or receive this medicine.</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->less than 1 mmol (or 23 mg) of <strong>sodium</strong> per 5 mL, that is to say essentially &lsquo;sodium free&rsquo;.</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->1.2 mg <strong>propylene glycol</strong> in 1 mL. If your baby is less than 4 weeks old, talk to your doctor or pharmacist before giving them this medicine, in particular if the baby is given other medicines that contain propylene glycol or alcohol.</p><p><strong>parahydroxybenzoate</strong>: it may cause allergic reactions (possibly delayed).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor, pharmacist or nurse if you are not sure.</p><p>How much to take</p><p>Adults (from 18&nbsp;years)</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->The recommended dose of VITRAKVI is 100 mg (5 mL), two times a day.</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->Your doctor will review your dose and change it as needed.</p><p>Children and adolescents</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->Your child&rsquo;s doctor will work out the right dose for your child based on their height and weight.</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->The maximum recommended dose is 100 mg (5 mL), two times a day.</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->Your child&rsquo;s doctor will review the dose and change it as needed.</p><p>How to take this medicine</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->VITRAKVI can be taken with or without food.</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->Do not eat grapefruit or drink grapefruit juice while taking this medicine.</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->Along with this medicine you need a bottle adapter (28 mm diameter) and a syringe that can be used to give medicines by mouth. Use a 1 mL syringe with 0.1 mL marks for doses less than 1 mL. Use a 5 mL syringe with 0.2 mL marks for doses of 1 mL or more.</p><p style="margin-left:15.55pt; text-indent:-7.05pt"><!--[if !supportLists]-->&middot; <!--[endif]-->Press the bottle cap and turn it anti-clockwise to open the bottle.</p><p style="margin-left:15.55pt; text-indent:-7.05pt"><!--[if !supportLists]-->&middot; <!--[endif]-->Put the bottle adapter into the bottle neck and make sure it is well fixed.</p><p style="margin-left:15.55pt; text-indent:-7.05pt"><!--[if !supportLists]-->&middot; <!--[endif]-->Push the plunger fully into the syringe and then put the syringe in the adapter opening. Turn the bottle upside down.</p><p style="margin-left:15.55pt; text-indent:-7.05pt"><!--[if !supportLists]-->&middot; <!--[endif]-->Fill the syringe with a small amount of solution by pulling the plunger down, then push the plunger upwards to remove any large bubbles that are in the syringe.</p><p style="margin-left:15.55pt; text-indent:-7.05pt"><!--[if !supportLists]-->&middot; <!--[endif]-->Pull the plunger down to the mark equal to the dose in mL prescribed by your doctor.</p><p style="margin-left:15.55pt; text-indent:-7.05pt"><!--[if !supportLists]-->&middot; <!--[endif]-->Turn the bottle the right way up and take the syringe out of the adapter.</p><p style="margin-left:15.55pt; text-indent:-7.05pt"><!--[if !supportLists]-->&middot; <!--[endif]-->Put the syringe in the mouth, pointing towards the inside of the cheek &ndash; this will help you swallow the medicine naturally. Slowly press the plunger in.</p><p style="margin-left:15.55pt; text-indent:-7.05pt"><!--[if !supportLists]-->&middot; <!--[endif]-->Put the bottle cap on and tightly close the bottle - leave the adapter in the bottle.</p><p>If necessary, VITRAKVI may be administered via a nasogastric feeding tube. For details how to do so, please ask your doctor, pharmacist or nurse.</p><p>If you take more VITRAKVI than you should</p><p>Talk to your doctor, pharmacist or nurse or go to a hospital straight away. Take the medicine pack and this leaflet with you.</p><p>If you miss a dose of VITRAKVI</p><p>Do not take a double dose to make up for a forgotten dose or if you vomit after taking this medicine. Take your next dose at the usual time.</p><p>If you stop taking VITRAKVI</p><p>Do not stop taking this medicine without talking to your doctor first. It is important to take VITRAKVI for as long as your doctor tells you.</p><p>If you are not able to take the medicine as your doctor prescribed talk to your doctor straight away.</p><p>If you have further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>You should <strong>immediately contact your doctor</strong> if you experience any of the following <strong>serious</strong> <strong>side effects:</strong></p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->feeling dizzy (very common side effect, may affect more than 1&nbsp;in 10&nbsp;people), tingling, feeling numb, or a burning feeling in your hands and feet, difficulty walking normally (common side effect, may affect up to 1&nbsp;in 10&nbsp;people). This could be symptoms of <strong>nervous system problems.</strong></p><p>Your doctor may decide to lower the dose, or pause or stop the treatment.</p><p>Tell your doctor, pharmacist or nurse if you notice any of the following side effects:</p><p>Very common (may affect more than 1&nbsp;in 10&nbsp;people):</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->you may look pale and feel your heart pumping, which could be symptoms of low red blood cells (anaemia)</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->flu like symptoms including fever, which could be symptoms of low white blood cells (neutropenia, leukopenia)</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->feeling or being sick (nausea or vomiting)</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->constipation</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->muscle pain (myalgia)</p><p style="margin-left:8.6pt; margin-right:0in">&nbsp;</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->feeling tired (fatigue)</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->increased amount of liver enzymes in blood tests</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->weight increase.</p><p>Common (may affect up to 1&nbsp;in 10&nbsp;people):</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->change in how things taste (dysgeusia)</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->muscle weakness</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->increased amount of &ldquo;alkaline phosphatase&rdquo; in blood tests (very common in children).</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</p><p><strong>To report any side effect(s):</strong></p><p>The National Pharmacovigilance Centre (NPC).</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->Keep this medicine out of the sight and reach of children.</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->Do not use this medicine after the expiry date which is stated on the carton and the bottle label after EXP. The expiry date refers to the last day of that month.</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->Store in a refrigerator (2 &deg;C - 8 &deg;C).</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->Do not freeze.</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->Once the bottle is open, you must use your medicine within 30 days of opening.</p><p style="margin-left:8.6pt; margin-right:0in; text-indent:-8.6pt"><!--[if !supportLists]-->-&nbsp;&nbsp; <!--[endif]-->Do not take the medicine if the bottle or bottle cap looks damaged or like it has leaked.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What VITRAKVI contains</p><p>The active substance is larotrectinib.</p><p>Each mL of oral solution contains 20 mg of larotrectinib (as sulfate).</p><p>The other ingredients are:</p><p style="margin-left:8.5pt; margin-right:0in; text-indent:-8.5pt"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->Purified water</p><p style="margin-left:8.5pt; margin-right:0in; text-indent:-8.5pt"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->Sucrose</p><p style="margin-left:8.5pt; margin-right:0in; text-indent:-8.5pt"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->Hydroxypropylbetadex</p><p style="margin-left:8.5pt; margin-right:0in; text-indent:-8.5pt"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->Glycerol (E 422)</p><p style="margin-left:8.5pt; margin-right:0in; text-indent:-8.5pt"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->Sorbitol (E 420)</p><p style="margin-left:8.5pt; margin-right:0in; text-indent:-8.5pt"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->Sodium citrate (E 331)</p><p style="margin-left:8.5pt; margin-right:0in; text-indent:-8.5pt"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->Sodium dihydrogen phosphate dihydrate (E 339)</p><p style="margin-left:8.5pt; margin-right:0in; text-indent:-8.5pt"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->Citric acid (E 330)</p><p style="margin-left:8.5pt; margin-right:0in; text-indent:-8.5pt"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->Propylene glycol (E 1520)</p><p style="margin-left:8.5pt; margin-right:0in; text-indent:-8.5pt"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->Potassium sorbate (E 202)</p><p style="margin-left:8.5pt; margin-right:0in; text-indent:-8.5pt"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->Methyl parahydroxybenzoate (E 218)</p><p style="margin-left:8.5pt; margin-right:0in; text-indent:-8.5pt"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->Citrus fruit flavour</p><p style="margin-left:8.5pt; margin-right:0in; text-indent:-8.5pt"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]-->Natural flavour</p><p>See &ldquo;VITRAKVI contains&rdquo; in section 2 for more information.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What VITRAKVI looks like and the contents of the bottle
VITRAKVI is a clear yellow to orange oral solution.
Each carton contains 1 child-resistant glass bottle containing 100 mL oral solution.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer:</strong></p><p>Penn Pharmaceutical Services Ltd,</p><p>United Kingdom.</p><p><strong>Marketing Authorisation Holder:</strong></p><p>Bayer AG,</p><p>Germany.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in July 2020.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ما هي دواعي استخدام ڤيتراكڤي<br />يحتوي ڤيتراكڤي على المادة الفعالة لاروتريكتينيب.<br />يتم استخدامه في البالغين والمراهقين والأطفال لعلاج الأورام الصلبة )السرطان( في أجزاء مختلفة من الجسم التي تسببها تغيير جينات<br />معينة تسمى )مستقبلات التغذية العصبية لكاينيز التايروسين( التي هي من عائلة البروتينات التي تحفز على بقاء الخلايا العصبية وأيضاً<br />على نموها وعلى وظيفتها.<br />دواعي استخدام ڤيتراكڤي فقط في الحالات الآتية<br />r هذه السرطانات متقدمة أو تنتشر إلى أجزاء أخرى من الجسم أو إذا كان من المحتمل أن تسبب العملية جراحية لإزالة السرطان<br />مضاعفات شديدة و<br />r لا توجد خيارات علاجية مُرضية.<br />قبل أن تحصل على ڤيتراكڤي، سيقوم طبيبك المعالج بإجراء اختبار لمعرفة ما إذا كان لديك تغيير في جينات معينة تسمى )مستقبلات<br />التغذية العصبية لكاينيز التايروسين( التي هي من عائلة البروتينات التي تحفز على بقاء الخلايا العصبية وأيضاً على نموها وعلى وظيفتها.<br />كيف يعمل ڤيتراكڤي<br />في المرضى المصابين بسرطان بسبب تغيير في جينات معينة تسمى )مستقبلات التغذية العصبية لكاينيز التايروسين( التي هي من عائلة<br />البروتينات التي تحفز على بقاء الخلايا العصبية وأيضاً على نموها وعلى وظيفتها، فإن التغيير في هذه الجينات يجعل الجسم ينتج بروتينات<br />غير طبيعية تسمى بروتينات الاندماج المرتبطة بكاينيز بروتين التروبوميوزين، والذي يمكن أن يؤدي إلى نمو الخلايا الغير منضبطة والسرطان.<br />يمنع ڤيتراكڤي عمل بروتينات الاندماج المرتبطة بكاينيز بروتين التروبوميوزين وبالتالي قد يبطئ أو يوقف نمو السرطان. قد يساعد أيضاً على<br />تقليص حجم السرطان.<br />إذا كان لديك أي أسئلة حول كيفية عمل ڤيتراكڤي أو لماذا تم وصفه لك، اسأل طبيبك المعالج، الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تستخدم ڤيتراكڤي في الحالات التالية<br />r لديك حساسية من لاروتريكتينيب أو أي من المكونات الأخرى لهذا الدواء )المذكورة في الجزء رقم 6(.<br />الاختبارات والفحوصات<br />يمكن أن يزيد ڤيتراكڤي من كمية إنزيمات الكبد ألانين أمينوترنسفراز وأسبارتات أمينوترنسفراز في دمك ) ALT و AST (. سيقوم طبيبك<br />المعالج بإجراء فحوصات الدم قبل وأثناء العلاج للتحقق من مستوى إنزيمات الكبد ALT و AST في دمك والتحقق من مدى جودة عمل<br />الكبد.<br />الأدوية الأخرى وڤيتراكڤي<br />أخبر طبيبك أو الصيدلي أو الممرض إذا كنت تتناول أو تناولت مؤخراً أو قد تتناول أي أدوية أخرى. وذلك لأن بعض الأدوية قد تؤثر على<br />طريقة عمل ڤيتراكڤي أو قد يؤثر ڤيتراكڤي على طريقة عمل الأدوية الأخرى.<br />خاصةً، أخبر طبيبك المعالج أو الصيدلي أو الممرض إذا كنت تتناول أياً من الأدوية التالية:<br />r الأدوية المستخدمة لعلاج العدوى الفطرية أو العدوى البكتيرية والتي تسمى إيتراكونازول، فوركونازول، كلاريثروميسين، تيليثروميسين،<br />ترولياندوميسين<br />r دواء يستخدم لعلاج متلازمة كوشينج الذي يُسمى الكيتوكونازول<br />r الأدوية المستخدمة لعلاج عدوى فيروس نقص المناعة البشرية والتي تسمى أتازانافير، إندينافير، نلفينافير، ريتونافير، ساكوينافير،<br />ريفابوتين، إيفافيرنز<br />r دواء يستخدم لعلاج الاكتئاب يسمى نيفازودون<br />r الأدوية المستخدمة لعلاج الصرع تسمى الفينيتوين، كاربامازيبين، الفينوباربيتال<br />r دواء مستخلص من الأعشاب الطبية يستخدم لعلاج الاكتئاب يسمى نبتة سانت جون<br />r دواء يستخدم لعلاج مرض السل يسمى ريفامبيسين<br />r دواء يستخدم لتخفيف الآلام القوية يسمى الفنتانيل<br />r الأدوية المستخدمة لمنع رفض الأعضاء بعد عملية زرع الأعضاء والتي تسمى سيكلوسبورين، سيروليموس، تاكروليموس<br />r دواء يستخدم لعلاج إيقاع القلب غير الطبيعي يسمى الكينيدين<br />r الأدوية المستخدمة لعلاج الصداع النصفي تسمى ديهيدروإرجوتامين، الإرجوتامين<br />r دواء يستخدم لعلاج الألم المزمن ويسمى الفنتانيل<br />r دواء يستخدم للسيطرة على الحركات الغير إرادية أو الأصوات الغير إرادية ويسمى هذا الدواء بيموزيد<br />r دواء لمساعدتك على التوقف عن التدخين يسمى البوبروبيون<br />r أدوية لخفض مستويات السكر في الدم تسمى ريباكلينيد، تولبوتاميد<br />r دواء يمنع تجلط الدم يسمى الوارفارين<br />r دواء يستخدم لتقليل كمية الحمض المنتجة في المعدة وهذا الدواء يسمى أوميبرازول<br />r دواء يستخدم للمساعدة في السيطرة على ارتفاع ضغط الدم يسمى فالسارتان<br />r مجموعة من الأدوية المستخدمة للمساعدة في خفض الكوليسترول وتسمى الستاتين<br />r الأدوية الهرمونية المستخدمة لمنع الحمل، انظر أدناه الجزء &laquo;وسائل منع الحمل - للرجال والنساء .&raquo;<br />إذا كان أي مما سبق ينطبق عليك )أو لم تكن متأكداً( ، فتحدث إلى طبيبك المعالج أو الصيدلي أو الممرض.<br />تفاعل ڤيتراكڤي مع الطعام والشراب<br />لا تتناول الجريب فروت، أو تشرب عصير الجريب فروت أثناء العلاج باستخدام ڤيتراكڤي. هذا لأنه قد يزيد من كمية ڤيتراكڤي في جسمك.<br />الحمل و الرضاعة الطبيعية<br />فترة الحمل<br />إذا كنتِ حاملاً، أو تعتقدين أنكِ حامل أو لديكِ خطة لإنجاب طفل، فاطلبي من طبيبك المعالج أو الصيدلي الحصول على المشورة قبل تناول<br />هذا الدواء.<br />يجب عدم استخدام ڤيتراكڤي أثناء الحمل لأن تأثير ڤيتراكڤي على الجنين غير معروف.<br />الرضاعة الطبيعية<br />لا تُرضعي طفلك أثناء تناول هذا الدواء ولمدة 3 أيام بعد آخر جرعة. هذا لأنه من غير المعروف ما إذا كان ڤيتراكڤي ينتقل إلى حليب الأم.<br />وسائل منع الحمل - للرجال والنساء<br />يجب تجنب الحمل أثناء تناول هذا الدواء.<br />إذا كنتِ قادرة أن تُصبحي حامل، يجب على طبيبك المعالج إجراء اختبار الحمل قبل البدء في العلاج. يجب استخدام وسائل فعالة لمنع<br />الحمل أثناء تناول ڤيتراكڤي ولمدة شهر على الأقل بعد آخر جرعة، وذلك في الحالات التالية<br />r أنتِ قادرة أن تصبحي حامل. إذا كنتِ تستخدمين وسائل منع الحمل الهرمونية، فيجب عليكِ أيضاً استخدام طريقة حاجزة، مثل الواقي<br />الذكري.<br />r تمارس الجنس مع امرأة لديها القدرة أن تصبح حامل.<br />اسألي طبيبك المعالج عن أفضل طريقة لمنع الحمل بالنسبة لكِ.<br />القيادة، ركوب الدراجات واستخدام الآلات<br />قد يجعلك ڤيتراكڤي تشعر بالدوار أو التعب. إذا حدث هذا، فلا تقم بقيادة السيارة، ركوب الدراجات أو استخدام أي أدوات أو أجهزة.<br />يحتوي ڤيتراكڤي على:<br />r السكروز: قد يكون ضاراً بالأسنان. إذا أخبرك طبيبك المعالج بأنك لا تتحمل بعض السكريات، فاتصل بطبيبك المعالج قبل تناول هذا<br />الدواء.<br />22 r مجم سوربيتول في 1 مللي لتر. السوربيتول هو مصدر للفركتوز. إذا أخبرك طبيبك بأنك أنت أو طفلك تعاني من عدم تحمل<br />بعض السكريات أو إذا كان قد تم تشخيصك بمرض عدم تحمل الفركتوز الوراثي، الذي هو اضطراب وراثي نادر لا يستطيع فيه الشخص<br />انحلال الفركتوز، تحدث إلى طبيبك المعالج قبل استخدام هذا الدواء.<br />r أقل من 1 مليمول )أو 23 مجم( من الصوديوم لكل 5 مللي لتر، وهذا يعني بشكل أساسي &laquo;خالي من الصوديوم .&raquo;<br />1.2r مجم بروبيلين جليكول في 1 مللي لتر. إذا كان عمر طفلك أقل من 4 أسابيع، فتحدث إلى طبيبك المعالج أو الصيدلي قبل<br />إعطائه هذا الدواء، خاصةً إذا كان الطفل يتناول أدوية أخرى تحتوي على البروبيلين جليكول أو الكحول.<br />r بارا هيدروكسي بنزوات: قد يسبب الحساسية )ربما تتأخر ظهور الحساسية(.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائماً تناول ڤيتراكڤي تماماً كما يخبرك طبيبك المعالج أو الصيدلي. استشر طبيبك المعالج، الصيدلي أو الممرض إذا كنت غير متأكد.<br />ما هي الجرعة التي يجب تناولها<br />البالغين )بدأً من 18 عاماً(<br />r جرعة ڤيتراكڤي الموصى بها هي 100 مجم ) 5 مللي لتر(، مرتين يومياً.<br />r سيقوم طبيبك المعالج بمراجعة الجرعة الخاصة بك وتغييرها حسب الحاجة.<br />المراهقين والأطفال<br />r سيقوم طبيب طفلك المعالج بإعداد الجرعة المناسبة لطفلك على أساس طوله ووزنه.<br />r الجرعة القصوى الموصى بها هي 100 مجم ) 5 مللي لتر(، مرتين يومياً.<br />r سيقوم طبيب طفلك المعالج بمراجعة الجرعة الخاصة بك وتغييرها حسب الحاجة.<br />كيفية تناول هذا الدواء<br />r يمكن تناول ڤيتراكڤي مع الطعام أو بدون طعام.<br />r لا تأكل الجريب فروت أو تشرب عصير الجريب فروت أثناء تناول هذا الدواء.<br />r إلى جانب هذا الدواء، تحتاج إلى محول زجاجة &ndash; واصلة )قطره 28 مم( ومحقنة يمكن استخدامها لإعطاء الأدوية عن طريق الفم.<br />استخدم محقنة 1 مللي لتر بها علامات كل 0.1 مللي لتر لجرعات أقل من 1 مللي لتر. استخدم محقنة 5 مللي لتر بها علامات كل<br />0.2 مللي لتر لجرعات 1 مللي لتر أو أكثر.<br />p أضغط على غطاء الزجاجة ويتم تحريك )لف( غطاء الزجاجة في عكس اتجاه عقارب الساعة لفتح الزجاجة.<br />p ضع محول الزجاجة &ndash; الواصلة في عنق الزجاجة وتأكد من ثباته جيداً.<br />p ادفع المكبس بالكامل في المحقنة ثم ضع المحقنة في فتحة محول الزجاجة &ndash; الواصلة. اقلب الزجاجة رأساً على عقب.<br />p يتم ملء المحقنة بكمية صغيرة من المحلول عن طريق سحب المكبس إلى أسفل، ثم دفع المكبس لأعلى لإزالة أي فقاعات كبيرة<br />موجودة في المحقنة.<br />p اسحب المكبس لأسفل إلى العلامة التي تساوي الجرعة الموصوفة من طبيبك المعالج.<br />p اقلب الزجاجة بالطريقة الصحيحة وأخرج المحقنة من محول الزجاجة &ndash; واصلة الزجاجة.<br />p ضع المحقنة في الفم، مشيراً إلى الداخل من الخد &ndash; سيساعدك ذلك على ابتلاع الدواء بشكل طبيعي. اضغط ببطء على المكبس.<br />p ضع غطاء الزجاجة وأغلق الزجاجة بإحكام &ndash; اترك محول الزجاجة &ndash; واصلة الزجاجة مرتبطة في الزجاجة.<br />إذا لزم الأمر، يمكن إعطاء ڤيتراكڤي عن طريق أنبوب التغذية الأنفي المعدي. للحصول على تفاصيل حول كيفية القيام بذلك، يرجى<br />سؤال طبيبك المعالج، الصيدلي أو الممرض.<br />إذا تناولت جرعة ڤيتراكڤي أكثر مما يجب<br />تحدث إلى طبيبك المعالج، الصيدلي أو الممرض أو اذهب إلى المستشفى على الفور. خذ عبوة الدواء وهذه النشرة معك.<br />إذا نسيت تناول جرعة من ڤيتراكڤي<br />لا تتناول جرعة مضاعفة لتعويض جرعة منسية أو إذا تقيأت بعد تناول هذا الدواء. تناول الجرعة التالية في الوقت المعتاد.<br />إذا توقفت عن تناول ڤيتراكڤي<br />لا تتوقف عن تناول هذا الدواء بدون التحدث إلى طبيبك المعالج أولاً. من المهم أن تتناول ڤيتراكڤي طالما يخبرك طبيبك المعالج بذلك.<br />إذا لم تكن قادراً على تناول الدواء كما وصفه لك طبيبك المعالج، تحدث إلى طبيبك المعالج على الفور.<br />إذا كانت لديك أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك المعالج، الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء آثار جانبية، إلا أنها لا تصيب الجميع.<br />يجب عليك الاتصال بطبيبك المعالج على الفور إذا واجهت أياً من الآثار الجانبية الخطيرة التالية:<br />r الشعور بالدوار )آثار جانبية شائعة جداً، يمكن أن تصيب أكثر من شخص واحد من بين كل 10 أشخاص( أو الوخز، أو الشعور بالخدر،<br />أو الشعور بتحرُّق في الجلد )المذل( في يديك وقدميك، صعوبة المشي بشكل طبيعي )آثار جانبية شائعة، يمكن أن تصيب حتى شخص<br />واحد من بين كل 10 أشخاص(. هذا يمكن أن يكون أعراض مشاكل الجهاز العصبي.<br />قد يقرر طبيبك خفض الجرعة، أو أن تتوقف مؤقتاً عن تناول العلاج أو التوقف بشكل دائم عن تناول العلاج.<br />أخبر طبيبك، الصيدلي أو الممرض إذا لاحظت أياً من الآثار الجانبية التالية.<br />شائعة جداً )قد تصيب أكثر من شخص واحد من كل 10 أشخاص(:<br />r قد تبدو شاحب اللون وتشعر بضخ قلبك، مما قد يكون من أعراض انخفاض خلايا الدم الحمراء )فقر الدم(<br />r أعراض شبيهة بالأنفلونزا، التي يمكن أن تكون من أعراض خلايا الدم البيضاء المنخفضة )قلة العدلات، نقص الكريات البيض(<br />r الشعور أو يصبح الشخص مريض )الغثيان أو القيء(<br />r الامساك<br />r الم العضلات )ألم عضلي(<br />r الشعور بالتعب )التعب(<br />r زيادة كمية أنزيمات الكبد في اختبارات الدم<br />r زيادة وزن الجسم.<br />شائعة )قد تصيب أكثر من شخص واحد من كل 10 أشخاص(:<br />r تغيير في كيفية تذوق الأشياء )خلل في التذوق(<br />r ضعف العضلات<br />r زيادة كمية &laquo;الفوسفاتاز القلوي &raquo; في اختبارات الدم )شائعة جداً عند الأطفال(.<br />الإبلاغ عن الآثار الجانبية<br />إذا تم إصابتك بأي آثار جانبية، تحدث مع طبيبك، الصيدلي أو الممرض. هذا يشمل أي آثار جانبية محتملة غير مذكورة في هذه النشرة.<br />يمكن أن تساعد من خلال الإبلاغ عن الآثار الجانبية على توفير مزيد من المعلومات عن سلامة هذا الدواء.<br />اللمر لإكبز لاالغو طعنني ألليت يأقعر ظا الد ضو ائجيانبية<br />فاكس: 7662 &ndash; 205 &ndash; 11 &ndash; 966 +<br />مركز اتصال الهيئة العامة للغذاء والدواء: 19999<br />البريد الالكتروني: npc.drug@sfda.gov.sa<br />الموقع الالكتروني: https://ade.sfda.gov.sa</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ هذا الدواء بعيداً عن نظر و متناول أيدي الأطفال.<br />r لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية الموضح بعد EXP على علبة الكرتون وعلى ملصق الزجاجة. يشير تاريخ انتهاء<br />الصلاحية إلى اليوم الأخير من ذلك الشهر.<br />r قم بالتخزين في الثلاجة )بين 2 درجة مئوية إلى 8 درجات مئوية(.<br />r يجب عدم تجميد المحلول.<br />r بمجرد فتح الزجاجة، يجب عليك استخدام الدواء الخاص بك في غضون 30 يوماً من فتح زجاجة الدواء.<br />r لا تتناول الدواء إذا كانت الزجاجة أو غطاء الزجاجة تالفاً أو كان قد تسرب منه الدواء للخارج.<br />r لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم<br />تعد تستخدمها. هذه التدابير سوف تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ما الذي يحتوي عليه ڤيتراكڤي<br />المادة الفعالة هي لاروتريكتينيب<br />كل مللي لتر من المحلول الذي يتم تناوله عن طريق الفم يحتوي على 20 مجم من لاروتريكتينيب )ككبريتات(.<br />المواد الغير فعالة الأخرى هي:<br />r الماء النقي<br />r السكروز<br />r هيدروكسي بروبيل بيتاديكس<br />r الجلسرين ) )E422<br />r السوربيتول ) )E420<br />r سترات الصوديوم ) )E331<br />r هيدروجين فوسفات الصوديوم ثنائي هيدرات ) )E339<br />r حامض الستريك ) )E330<br />r بروبيلين جليكول ) )E1520<br />r سوربات البوتاسيوم ) )E202<br />r ميثيل باراهيدروكسي بينزوات ) )E218<br />r نكهة الحمضيات<br />r نكهة طبيعية<br />لمزيد من المعلومات انظر &laquo;يحتوي ڤيتراكڤي &raquo; في الجزء رقم 2.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>كيف يبدو ڤيتراكڤي وما هي محتويات العبوة<br />ڤيتراكڤي محلول يؤخَذ الفم هو محلول صافي لونه من الأصفر إلى البرتقالي.<br />كل علبة تحتوي على زجاجة واحدة مصنوعة من الزجاج مغلقة بغطاء مقاوم لمحاولة فتحه من الطفل تحتوي على 100 مللي لتر محلول<br />يؤخَذ بالفم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>المصنع:<br />بين فارماسوتيكال سيرفيسيز ليميتد<br />المملكة المتحدة.<br />مالك حق التسويق<br />باير إيه.جي.<br />ألمانيا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة في يوليو 2020 .
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                VITRAKVI 20 mg/mL oral solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each mL of oral solution contains larotrectinib sulfate equivalent to 20 mg of larotrectinib.

Excipients with known effect:
Each mL of oral solution contains 295 mg sucrose, 22 mg sorbitol, 1.2 mg propylene glycol and 0.2 mg methyl parahydroxybenzoate.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oral solution.

Clear yellow to orange solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>VITRAKVI as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (<em>NTRK</em>) gene fusion,</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->who have no satisfactory treatment options (see sections&nbsp;4.4 and&nbsp;5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with VITRAKVI should be initiated by physicians experienced in the administration of anticancer therapies.</p><p>&nbsp;</p><p>The presence of an <em>NTRK</em> gene fusion in a tumour specimen should be confirmed by a validated test prior to initiation of treatment with VITRAKVI.</p><p>&nbsp;</p><p>Posology</p><p>&nbsp;</p><p>Adults</p><p>The recommended dose in adults is 100&nbsp;mg larotrectinib twice daily, until disease progression or until unacceptable toxicity occurs.</p><p>&nbsp;</p><p>Paediatric population</p><p>Dosing in paediatric patients is based on body surface area (BSA). The recommended dose in paediatric patients is 100&nbsp;mg/m2 larotrectinib twice daily with a maximum of 100&nbsp;mg per dose until disease progression or until unacceptable toxicity occurs.</p><p><em>Missed dose</em></p><p>If a dose is missed, the patient should not take two doses at the same time to make up for a missed dose. Patients should take the next dose at the next scheduled time. If the patient vomits after taking a dose, the patient should not take an additional dose to make up for vomiting.</p><p>&nbsp;</p><p>Dose modification</p><p>For all Grade&nbsp;2 adverse reactions, continued dosing may be appropriate, though close monitoring to ensure no worsening of the toxicity is advised. Patients with Grade&nbsp;2 ALT and/or AST increases, should be followed with serial laboratory evaluations every one to two weeks after the observation of Grade&nbsp;2 toxicity until resolved to establish whether a dose interruption or reduction is required.</p><p>&nbsp;</p><p>For Grade&nbsp;3 or&nbsp;4 adverse reactions:</p><p style="margin-left:28.35pt; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->VITRAKVI should be withheld until the adverse reaction resolves or improves to baseline or Grade&nbsp;1. Resume at the next dose modification if resolution occurs within 4&nbsp;weeks.</p><p style="margin-left:28.35pt; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->VITRAKVI should be permanently discontinued if an adverse reaction does not resolve within 4&nbsp;weeks.</p><p>&nbsp;</p><p>The recommended dose modifications for VITRAKVI for adverse reactions are provided in Table&nbsp;1.</p><p>&nbsp;</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt">Table&nbsp;1: Recommended dose modifications for VITRAKVI for adverse reactions</p><table cellspacing="0" cellpadding="0" border="1" style="width:97.22%"><tbody><tr><td style="height:14.2pt; width:26.32%"><p style="text-align:center">Dose modification</p></td><td style="height:14.2pt; width:36.84%"><p>Adult and</p><p>paediatric patients with body surface area of at least 1.0&nbsp;m<sup>2</sup></p></td><td style="height:14.2pt; width:36.84%"><p>Paediatric patients with body surface area less than 1.0&nbsp;m<sup>2</sup></p></td></tr><tr><td style="height:31.0pt; width:26.32%"><p>First</p></td><td style="height:31.0pt; width:36.84%"><p style="margin-left:0in; margin-right:0in">75&nbsp;mg twice daily</p></td><td style="height:31.0pt; width:36.84%"><p style="margin-left:0in; margin-right:0in">75&nbsp;mg/m<sup>2</sup> twice daily</p></td></tr><tr><td style="height:31.9pt; width:26.32%"><p>Second</p></td><td style="height:31.9pt; width:36.84%"><p style="margin-left:0in; margin-right:0in">50&nbsp;mg twice daily</p></td><td style="height:31.9pt; width:36.84%"><p style="margin-left:0in; margin-right:0in">50&nbsp;mg/m<sup>2</sup> twice daily</p></td></tr><tr><td style="height:28.4pt; width:26.32%"><p>Third</p></td><td style="height:28.4pt; width:36.84%"><p style="margin-left:0in; margin-right:0in">100&nbsp;mg once daily</p></td><td style="height:28.4pt; width:36.84%"><p style="margin-left:0in; margin-right:0in">25&nbsp;mg/m<sup>2</sup> twice daily<sup>a</sup></p></td></tr></tbody></table><p style="margin-left:7.1pt; margin-right:0in; text-indent:-7.1pt"><sup>a&nbsp;&nbsp; </sup>Paediatric patients on 25&nbsp;mg/m&sup2; twice daily should remain on this dose even if body surface area becomes greater 1.0&nbsp;m&sup2; during the treatment. Maximum dose should be 25&nbsp;mg twice daily at the third dose modification.</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">VITRAKVI should be permanently discontinued in patients who are unable to tolerate VITRAKVI after three dose modifications.</p><p>&nbsp;</p><p>Special populations</p><p>&nbsp;</p><p>Elderly</p><p>No dose adjustment is recommended in elderly patients (see section&nbsp;5.2).</p><p>&nbsp;</p><p>Hepatic impairment</p><p>The starting dose of VITRAKVI should be reduced by 50% in patients with moderate (Child‑Pugh&nbsp;B) to severe (Child‑Pugh&nbsp;C) hepatic impairment. No dose adjustment is recommended for patients with mild hepatic impairment (Child‑Pugh&nbsp;A) (see section&nbsp;5.2).</p><p>&nbsp;</p><p>Renal impairment</p><p>No dose adjustment is required for patients with renal impairment (see section&nbsp;5.2).</p><p><em>&nbsp;</em></p><p>Co‑administration with strong CYP3A4 inhibitors</p><p>If co‑administration with a strong CYP3A4 inhibitor is necessary, the VITRAKVI dose should be reduced by 50%. After the inhibitor has been discontinued for 3&nbsp;to&nbsp;5 elimination half‑lives, VITRAKVI should be resumed at the dose taken prior to initiating the CYP3A4 inhibitor (see section&nbsp;4.5).</p><p>Method of administration</p><p>&nbsp;</p><p>VITRAKVI is for oral use.</p><p>&nbsp;</p><p>VITRAKVI is available as a capsule or oral solution with equivalent oral bioavailability and may be used interchangeably.</p><p>&nbsp;</p><p>The oral solution should be administered by mouth using an oral syringe of 1&nbsp;mL or 5&nbsp;mL volume or enterally by using a nasogastric feeding tube.</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->For doses below 1&nbsp;mL a 1&nbsp;mL oral syringe should be used. The calculated dose volume should be rounded to the nearest 0.1&nbsp;mL.</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->For doses of 1&nbsp;mL and higher a 5&nbsp;mL oral syringe should be used. The dose volume should be calculated to the nearest 0.2&nbsp;mL.</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->VITRAKVI should not be mixed with feeding formulas, if administered via nasogastric feeding tube. Mixing with the feeding formulas could lead to tube blockages.</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->For instructions for use of oral syringes and feeding tubes see section&nbsp;6.6.</p><p>&nbsp;</p><p>The oral solution can be taken with or without food but should not be taken with grapefruit or grapefruit juice.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Efficacy across tumour types</p><p>&nbsp;</p><p>The benefit of VITRAKVI has been established in single arm trials encompassing a relatively small sample of patients whose tumours exhibit <em>NTRK</em> gene fusions. Favourable effects of VITRAKVI have been shown on the basis of overall response rate and response duration in a limited number of tumour types. The effect may be quantitatively different depending on tumour type, as well as on concomitant genetic alterations (see section&nbsp;5.1). For these reasons, VITRAKVI should only be used if there are no treatment options for which clinical benefit has been established, or where such treatment options have been exhausted (i.e., no satisfactory treatment options).</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p><p>Neurologic reactions</p><p>&nbsp;</p><p>Neurologic reactions including dizziness, gait disturbance and paraesthesia were reported in patients receiving larotrectinib (see section&nbsp;4.8). For the majority of neurologic reactions, onset occurred within the first three months of treatment. Withholding, reducing, or discontinuing VITRAKVI dosing should be considered, depending on the severity and persistence of these symptoms (see section&nbsp;4.2).</p><p>&nbsp;</p><p>Transaminase elevations</p><p>&nbsp;</p><p>ALT and AST increase were reported in patients receiving larotrectinib (see section&nbsp;4.8). The majority of ALT and AST increases occurred in the first 3&nbsp;months of treatment.</p><p>Liver function including ALT and AST assessments should be monitored before the first dose and monthly for the first 3&nbsp;months of treatment, then periodically during treatment, with more frequent testing in patients who develop transaminase elevations. Withhold or permanently discontinue VITRAKVI based on the severity. If withheld, the VITRAKVI dose should be modified when resumed (see section&nbsp;4.2).</p><p>Co‑administration with CYP3A4/P‑gp inducers</p><p>&nbsp;</p><p>Avoid co‑administration of strong or moderate CYP3A4/P‑gp inducers with VITRAKVI due to a risk of decreased exposure (see section&nbsp;4.5).</p><p>&nbsp;</p><p><u>Contraception in female and male</u></p><p>&nbsp;</p><p>Women of childbearing potential must use highly effective contraception while taking VITRAKVI and for at least one month after stopping treatment (see sections&nbsp;4.5 and 4.6).</p><p>Males of reproductive potential with a non‑pregnant woman partner of child bearing potential should be advised to use highly effective contraception during treatment with VITRAKVI and for at least one month after the final dose (see section&nbsp;4.6).</p><p>&nbsp;</p><p><u>Important information about some of the ingredients</u></p><p><u>Sucrose:</u> may be harmful to the teeth. Patients with rare hereditary problems of fructose intolerance, glucose‑galactose malabsorption or sucrose‑isomaltase insufficiency should not take this medicinal product.</p><p><u>Sorbitol:</u> patients with hereditary fructose intolerance (HFI) should not take this medicinal product.</p><p><u>Sodium:</u> this medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per 5&nbsp;mL, that is to say essentially &lsquo;sodium‑free&rsquo;.</p><p><u>Propylene glycol:</u> co‑administration with any substrate for alcohol dehydrogenase such as ethanol may induce serious adverse effects in neonates.</p><p><u>Parahydroxybenzoate</u>: may cause allergic reactions (possibly delayed).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects of other agents on larotrectinib</p><p>&nbsp;</p><p><em>Effect of CYP3A, P‑gp and BCRP inhibitors on larotrectinib</em></p><p>Larotrectinib is a substrate of cytochrome P450 (CYP) 3A, P‑glycoprotein (P‑gp) and breast cancer resistance protein (BCRP). Co‑administration of VITRAKVI with strong CYP3A inhibitors, P‑gp and BCRP inhibitors (e.g. atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole or grapefruit) may increase larotrectinib plasma concentrations (see section&nbsp;4.2).</p><p>Clinical data in healthy adult subjects indicate that co‑administration of a single 100&nbsp;mg VITRAKVI dose with itraconazole (a strong CYP3A inhibitor and P‑gp and BCRP inhibitor) 200&nbsp;mg once daily for 7&nbsp;days increased larotrectinib Cmax and AUC by 2.8‑fold and 4.3‑fold, respectively.</p><p>Clinical data in healthy adult subjects indicate that co‑administration of a single 100&nbsp;mg VITRAKVI dose with a single dose of 600&nbsp;mg rifampin (a P‑gp and BCRP inhibitor) increased larotrectinib Cmax and AUC by 1.8‑fold and 1.7‑fold, respectively.</p><p>&nbsp;</p><p><em>Effect of CYP3A and P‑gp inducers on larotrectinib</em></p><p>Co‑administration of VITRAKVI with strong or moderate CYP3A and P‑gp inducers (e.g. carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, or St. John&rsquo;s Wort) may decrease larotrectinib plasma concentrations and should be avoided (see section&nbsp;4.4).</p><p>Clinical data in healthy adult subjects indicate that co‑administration of a single 100&nbsp;mg VITRAKVI dose with rifampin (a strong CYP3A and P‑gp inducer) 600&nbsp;mg twice daily for 11&nbsp;days decreased larotrectinib Cmax and AUC by 71% and 81%, respectively. No clinical data is available on the effect of a moderate inducer, but a decrease in larotrectinib exposure is expected.</p><p>Effects of larotrectinib on other agents</p><p>&nbsp;</p><p><em>Effect of larotrectinib on CYP3A substrates</em></p><p>Clinical data in healthy adult subjects indicate that co‑administration of VITRAKVI (100&nbsp;mg twice daily for 10&nbsp;days) increased the Cmax and AUC of oral midazolam 1.7‑fold compared to midazolam alone, suggesting that larotrectinib is a weak inhibitor of CYP3A.</p><p>Exercise caution with concomitant use of CYP3A substrates with narrow therapeutic range (e.g. alfentanil, ciclosporin, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, or tacrolimus) in patients taking VITRAKVI. If concomitant use of these CYP3A substrates with narrow therapeutic range is required in patients taking VITRAKVI, dose reductions of the CYP3A substrates may be required due to adverse reactions.</p><p><u>&nbsp;</u></p><p><em>Effect of larotrectinib on CYP2B6 substrates</em></p><p><em>In vitro </em>studies indicate that larotrectinib induces CYP2B6. Co‑administration of larotrectinib with CYP2B6 substrates (e.g. bupropion, efavirenz) may decrease their exposure.</p><p>&nbsp;</p><p><em>Effect of larotrectinib on other transporter substrates</em></p><p><em>In vitro </em>studies indicate that larotrectinib is an inhibitor of OATP1B1. No clinical studies have been performed to investigate interactions with OATP1B1 substrates. Therefore, it cannot be excluded whether co‑administration of larotrectinib with OATP1B1 substrates (e.g. valsartan, statins) may increase their exposure.</p><p>&nbsp;</p><p><em>Effect of larotrectinib on substrates of PXR regulated enzymes</em></p><p><em>In vitro </em>studies indicate that larotrectinib is a weak inducer of PXR regulated enzymes (e.g. CYP2C family and UGT). Co‑administration of larotrectinib with CYP2C8, CYP2C9 or CYP2C19 substrates (e.g. repaglinide, warfarin, tolbutamide or omeprazole) may decrease their exposure.</p><p>&nbsp;</p><p><em>Hormonal contraceptives</em></p><p>It is currently unknown whether larotrectinib may reduce the effectiveness of systemically acting hormonal contraceptives. Therefore, women using systemically acting hormonal contraceptives should be advised to add a barrier method.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of childbearing potential / Contraception in males and females</p><p>&nbsp;</p><p>Based on the mechanism of action, foetal harm cannot be excluded when administering larotrectinib to a pregnant woman. Women of childbearing potential should have a pregnancy test prior to starting treatment with VITRAKVI.</p><p>Women of reproductive potential should be advised to use highly effective contraception during treatment with VITRAKVI and for at least one month after the final dose. As it is currently unknown whether larotrectinib may reduce the effectiveness of systemically acting hormonal contraceptives, women using systemically acting hormonal contraceptives should be advised to add a barrier method.</p><p>Males of reproductive potential with a non‑pregnant woman partner of child‑bearing potential should be advised to use highly effective contraception during treatment with VITRAKVI and for at least one month after the final dose.</p><p>&nbsp;</p><p>Pregnancy</p><p>&nbsp;</p><p>There are no data from the use of larotrectinib in pregnant women.</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section&nbsp;5.3).</p><p>As a precautionary measure, it is preferable to avoid the use of VITRAKVI during pregnancy.</p><p>Breast‑feeding</p><p>&nbsp;</p><p>It is unknown whether larotrectinib/metabolites are excreted in human milk.</p><p>A risk to the newborns/infants cannot be excluded.</p><p>Breast‑feeding should be discontinued during treatment with VITRAKVI and for 3&nbsp;days following the final dose.</p><p>&nbsp;</p><p>Fertility</p><p>&nbsp;</p><p>There are no clinical data on the effect of larotrectinib on fertility. No relevant effects on fertility were observed in repeat‑dose toxicity studies (see section&nbsp;5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>VITRAKVI has a moderate influence on the ability to drive and use machines. Dizziness and fatigue have been reported in patients receiving larotrectinib, mostly Grade&nbsp;1 and&nbsp;2 during the first 3&nbsp;months of treatment. This may influence the ability to drive and use machines during this time period. Patients should be advised not to drive and use machines, until they are reasonably certain VITRAKVI therapy does not affect them adversely (see section&nbsp;4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile</p><p>&nbsp;</p><p>The most common adverse drug reactions (&ge;&nbsp;20%) of VITRAKVI in order of decreasing frequency were increased ALT (32%), fatigue (30%), constipation (29%), increased AST (27%), dizziness (26%), vomiting (23%), anaemia (23%), and nausea (22%).</p><p>The majority of adverse reactions were Grade&nbsp;1 or 2. Grade&nbsp;4 was the highest reported grade for adverse reactions neutrophil count decreased (1%), ALT increased (1%), and AST increased (&lt;&nbsp;1%). The highest reported grade was Grade&nbsp;3 for adverse reactions anaemia, weight increased, fatigue, dizziness, paraesthesia, muscular weakness, nausea, myalgia, gait disturbance, vomiting, and leukocyte count decreased. All the reported Grade&nbsp;3 adverse reactions occurred in less than 5% of patients, with the exception of anaemia (8%).</p><p>Permanent discontinuation of VITRAKVI for treatment emergent adverse reactions, regardless of attribution occurred in 5% of patients (one case each of ALT increased, AST increased, bile duct adenocarcinoma, gait disturbance, intestinal perforation, jaundice, malignant neoplasm progression, neutrophil count decreased, small intestinal obstruction, spinal cord compression, and viral infection). The majority of adverse reactions leading to dose reduction occurred in the first three months of treatment.</p><p>&nbsp;</p><p>Tabulated list of adverse reactions</p><p>&nbsp;</p><p>The safety of VITRAKVI was evaluated in 196&nbsp;patients with TRK fusion‑positive cancer in one of three on‑going clinical trials, Studies&nbsp;1, 2 (&ldquo;NAVIGATE&rdquo;), and 3 (&ldquo;SCOUT&rdquo;). The safety population characteristics were comprised of patients with a median age of 37.5&nbsp;years (range: 0.1, 84) with 37% of patients being paediatric patients. Median time on treatment for the overall safety population (n=196) was 9.3&nbsp;months (range: 0.10, 51.6).</p><p>The adverse drug reactions reported in patients (n=196) treated with VITRAKVI are shown in Table&nbsp;2 and Table&nbsp;3.</p><p>&nbsp;</p><p>The adverse drug reactions are classified according to the System Organ Class.</p><p>Frequency groups are defined by the following convention: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare (&lt;&nbsp;1/10,000), and not known (cannot be estimated from available data).</p><p>Within each frequency group, undesirable effects are presented in order of decreasing seriousness.</p><p><strong>Table&nbsp;2: Adverse drug reactions reported in TRK fusion‑positive cancer patients treated with VITRAKVI at recommended dose (overall safety population, n=196)</strong></p><table cellspacing="0" cellpadding="0" border="1" style="width:597px"><tbody><tr><td style="vertical-align:top; width:113.4pt"><p><strong>System organ class</strong></p></td><td style="vertical-align:top; width:76.55pt"><p style="margin-left:2.4pt; margin-right:0in">Frequency</p></td><td style="vertical-align:top; width:133.25pt"><p>All grades</p></td><td style="vertical-align:top; width:124.7pt"><p>Grades&nbsp;3 and&nbsp;4</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:113.4pt"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top; width:76.55pt"><p style="margin-left:2.4pt; margin-right:0in">Very common</p></td><td style="vertical-align:top; width:133.25pt"><p>Anaemia</p><p>Neutrophil count decreased (Neutropenia)</p><p>Leukocyte count decreased (Leukopenia)</p></td><td style="vertical-align:top; width:124.7pt"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:76.55pt"><p style="margin-left:2.4pt; margin-right:0in">Common</p></td><td style="vertical-align:top; width:133.25pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:124.7pt"><p>Anaemia</p><p>Neutrophil count decreased (Neutropenia)<sup>a</sup></p></td></tr><tr><td style="vertical-align:top; width:76.55pt"><p style="margin-left:2.4pt; margin-right:0in">Uncommon</p></td><td style="vertical-align:top; width:133.25pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:124.7pt"><p>Leukocyte count decreased (Leukopenia)</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:113.4pt"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:76.55pt"><p style="margin-left:2.4pt; margin-right:0in">Very common</p></td><td style="vertical-align:top; width:133.25pt"><p>Dizziness</p></td><td style="vertical-align:top; width:124.7pt"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:76.55pt"><p style="margin-left:2.4pt; margin-right:0in">Common</p></td><td style="vertical-align:top; width:133.25pt"><p>Gait disturbance</p><p>Paraesthesia</p></td><td style="vertical-align:top; width:124.7pt"><p>Dizziness</p><p>Paraesthesia</p></td></tr><tr><td style="vertical-align:top; width:76.55pt"><p style="margin-left:2.4pt; margin-right:0in">Uncommon</p></td><td style="vertical-align:top; width:133.25pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:124.7pt"><p>Gait disturbance</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:113.4pt"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top; width:76.55pt"><p style="margin-left:2.4pt; margin-right:0in">Very common</p></td><td style="vertical-align:top; width:133.25pt"><p>Nausea</p><p>Constipation</p><p>Vomiting</p></td><td style="vertical-align:top; width:124.7pt"><p>&nbsp;</p></td></tr><tr><td style="height:14.15pt; vertical-align:top; width:76.55pt"><p style="margin-left:2.4pt; margin-right:0in">Common</p></td><td style="height:14.15pt; vertical-align:top; width:133.25pt"><p>Dysgeusia<sup>b</sup></p></td><td style="height:14.15pt; vertical-align:top; width:124.7pt"><p>&nbsp;</p></td></tr><tr><td style="height:14.15pt; vertical-align:top; width:76.55pt"><p style="margin-left:2.4pt; margin-right:0in">Uncommon</p></td><td style="height:14.15pt; vertical-align:top; width:133.25pt"><p>&nbsp;</p></td><td style="height:14.15pt; vertical-align:top; width:124.7pt"><p>Nausea</p><p>Vomiting</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:113.4pt"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top; width:76.55pt"><p style="margin-left:2.4pt; margin-right:0in">Very common</p></td><td style="vertical-align:top; width:133.25pt"><p>Myalgia</p></td><td style="vertical-align:top; width:124.7pt"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:76.55pt"><p style="margin-left:2.4pt; margin-right:0in">Common</p></td><td style="vertical-align:top; width:133.25pt"><p>Muscular weakness</p></td><td style="vertical-align:top; width:124.7pt"><p>Myalgia</p><p>Muscular weakness</p></td></tr><tr><td rowspan="2" style="height:17.0pt; vertical-align:top; width:113.4pt"><p>General disorders and administration site conditions</p></td><td style="height:17.0pt; vertical-align:top; width:76.55pt"><p style="margin-left:2.4pt; margin-right:0in">Very common</p></td><td style="height:17.0pt; vertical-align:top; width:133.25pt"><p>Fatigue</p></td><td style="height:17.0pt; vertical-align:top; width:124.7pt"><p>&nbsp;</p></td></tr><tr><td style="height:17.0pt; vertical-align:top; width:76.55pt"><p style="margin-left:2.4pt; margin-right:0in">Common</p></td><td style="height:17.0pt; vertical-align:top; width:133.25pt"><p>&nbsp;</p></td><td style="height:17.0pt; vertical-align:top; width:124.7pt"><p>Fatigue</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:113.4pt"><p>Investigations</p></td><td style="vertical-align:top; width:76.55pt"><p style="margin-left:2.4pt; margin-right:0in">Very common</p></td><td style="vertical-align:top; width:133.25pt"><p>Alanine aminotransferase (ALT) increased</p><p>Aspartate aminotransferase (AST) increased</p><p>Weight increased (Abnormal weight gain)</p></td><td style="vertical-align:top; width:124.7pt"><p>&nbsp;</p></td></tr><tr><td style="height:87.85pt; vertical-align:top; width:76.55pt"><p style="margin-left:2.4pt; margin-right:0in">Common</p></td><td style="height:87.85pt; vertical-align:top; width:133.25pt"><p>Blood alkaline phosphatase increased</p></td><td style="height:87.85pt; vertical-align:top; width:124.7pt"><p>Alanine aminotransferase (ALT) increased<sup>a</sup></p><p>Aspartate aminotransferase (AST) increased<sup>a</sup></p><p>Weight increased (Abnormal weight gain)</p></td></tr></tbody></table><p style="margin-left:7.1pt; text-align:justify; text-indent:-7.1pt"><sup>a&nbsp;&nbsp; </sup>Grade&nbsp;4 reactions were reported</p><p style="margin-left:7.1pt; text-align:justify; text-indent:-7.1pt"><sup>b</sup>&nbsp; ADR dysgeusia includes the preferred terms &ldquo;dysgeusia&rdquo; and &ldquo;taste disorder&rdquo;</p><p><strong>Table&nbsp;3: Adverse drug reactions reported in TRK fusion‑positive paediatric cancer patients treated with VITRAKVI at recommended dose (n=73); all Grades</strong></p><table cellspacing="0" cellpadding="0" border="1" style="width:616px"><tbody><tr><td style="vertical-align:top; width:87.85pt"><p><strong>System organ class</strong></p></td><td style="vertical-align:top; width:56.7pt"><p style="margin-left:1.4pt; margin-right:0in">Frequency</p></td><td style="vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Infants and toddlers</p><p style="margin-left:1.4pt; margin-right:0in">(n=29)<sup>a</sup></p></td><td style="vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Children</p><p style="margin-left:1.4pt; margin-right:0in">&nbsp;</p><p style="margin-left:1.4pt; margin-right:0in">(n=30)<sup>b</sup></p></td><td style="vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Adolescents</p><p style="margin-left:1.4pt; margin-right:0in">&nbsp;</p><p style="margin-left:1.4pt; margin-right:0in">(n=14)<sup>c</sup></p></td><td style="vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Paediatric patients</p><p style="margin-left:1.4pt; margin-right:0in">(n=73)</p></td></tr><tr><td style="height:90.7pt; vertical-align:top; width:87.85pt"><p>Blood and lymphatic system disorders</p></td><td style="height:90.7pt; vertical-align:top; width:56.7pt"><p style="margin-left:1.4pt; margin-right:0in">Very common</p></td><td style="height:90.7pt; vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Anaemia</p><p style="margin-left:1.4pt; margin-right:0in">Neutrophil count decreased (Neutropenia)</p><p>Leukocyte count decreased (Leukopenia)</p></td><td style="height:90.7pt; vertical-align:top; width:79.35pt"><p>Anaemia</p><p>Neutrophil count decreased (Neutropenia)</p><p style="margin-left:1.4pt; margin-right:0in">Leukocyte count decreased (Leukopenia)</p></td><td style="height:90.7pt; vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Neutrophil count decreased (Neutropenia)</p><p style="margin-left:1.4pt; margin-right:0in">Leukocyte count decreased (Leukopenia)</p></td><td style="height:90.7pt; vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Anaemia</p><p style="margin-left:1.4pt; margin-right:0in">Neutrophil count decreased (Neutropenia)</p><p style="margin-left:1.4pt; margin-right:0in">Leukocyte count decreased (Leukopenia)</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:87.85pt"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:56.7pt"><p style="margin-left:1.4pt; margin-right:0in">Very common</p></td><td style="vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">&nbsp;</p></td><td style="vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">&nbsp;</p></td><td style="vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Dizziness</p></td><td style="vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:56.7pt"><p style="margin-left:1.4pt; margin-right:0in">Common</p></td><td style="vertical-align:top; width:79.35pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:79.35pt"><p>Dizziness</p><p>Paraesthesia</p><p style="margin-left:1.4pt; margin-right:0in">Gait disturbance</p></td><td style="vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Paraesthesia</p></td><td style="vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Dizziness</p><p style="margin-left:1.4pt; margin-right:0in">Paraesthesia</p><p style="margin-left:1.4pt; margin-right:0in">Gait disturbance</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:87.85pt"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top; width:56.7pt"><p style="margin-left:1.4pt; margin-right:0in">Very common</p></td><td style="vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Nausea</p><p style="margin-left:1.4pt; margin-right:0in">Constipation</p><p>Vomiting</p></td><td style="vertical-align:top; width:79.35pt"><p>Nausea</p><p>Constipation</p><p style="margin-left:1.4pt; margin-right:0in">Vomiting</p></td><td style="vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Nausea</p><p style="margin-left:1.4pt; margin-right:0in">Vomiting</p></td><td style="vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Nausea</p><p style="margin-left:1.4pt; margin-right:0in">Constipation</p><p style="margin-left:1.4pt; margin-right:0in">Vomiting</p></td></tr><tr><td style="height:14.15pt; vertical-align:top; width:56.7pt"><p style="margin-left:1.4pt; margin-right:0in">Common</p></td><td style="height:14.15pt; vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">&nbsp;</p></td><td style="height:14.15pt; vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Dysgeusia</p></td><td style="height:14.15pt; vertical-align:top; width:79.35pt"><p>Constipation</p></td><td style="height:14.15pt; vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Dysgeusia</p></td></tr><tr><td style="height:36.15pt; vertical-align:top; width:87.85pt"><p>Musculoskeletal and connective tissue disorders</p></td><td style="height:36.15pt; vertical-align:top; width:56.7pt"><p style="margin-left:1.4pt; margin-right:0in">Common</p></td><td style="height:36.15pt; vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">&nbsp;</p></td><td style="height:36.15pt; vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Myalgia</p><p style="margin-left:1.4pt; margin-right:0in">Muscular weakness</p></td><td style="height:36.15pt; vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Myalgia</p><p style="margin-left:1.4pt; margin-right:0in">Muscular weakness</p></td><td style="height:36.15pt; vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Myalgia</p><p style="margin-left:1.4pt; margin-right:0in">Muscular weakness</p></td></tr><tr><td style="height:50.6pt; vertical-align:top; width:87.85pt"><p>General disorders and administration site conditions</p></td><td style="height:50.6pt; vertical-align:top; width:56.7pt"><p style="margin-left:1.4pt; margin-right:0in">Very common</p></td><td style="height:50.6pt; vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Fatigue</p></td><td style="height:50.6pt; vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Fatigue</p></td><td style="height:50.6pt; vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Fatigue</p></td><td style="height:50.6pt; vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Fatigue</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:87.85pt"><p>Investigations</p></td><td style="vertical-align:top; width:56.7pt"><p style="margin-left:1.4pt; margin-right:0in">Very common</p></td><td style="vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Alanine aminotransferase (ALT) increased</p><p style="margin-left:1.4pt; margin-right:0in">Aspartate aminotransferase (AST) increased</p><p>Weight increased (Abnormal weight gain)</p><p>Blood alkaline phosphatase increased</p></td><td style="vertical-align:top; width:79.35pt"><p>Alanine aminotransferase (ALT) increased</p><p>Aspartate aminotransferase (AST) increased</p><p style="margin-left:1.4pt; margin-right:0in">Blood alkaline phosphatase increased</p></td><td style="vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Alanine aminotransferase (ALT) increased</p><p style="margin-left:1.4pt; margin-right:0in">Aspartate aminotransferase (AST) increased</p><p style="margin-left:1.4pt; margin-right:0in">Blood alkaline phosphatase increased</p></td><td style="vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Alanine aminotransferase (ALT) increased</p><p style="margin-left:1.4pt; margin-right:0in">Aspartate aminotransferase (AST) increased</p><p style="margin-left:1.4pt; margin-right:0in">Weight increased (Abnormal weight gain)</p><p style="margin-left:1.4pt; margin-right:0in">Blood alkaline phosphatase increased</p></td></tr><tr><td style="height:42.5pt; vertical-align:top; width:56.7pt"><p style="margin-left:1.4pt; margin-right:0in">Common</p></td><td style="height:42.5pt; vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">&nbsp;</p></td><td style="height:42.5pt; vertical-align:top; width:79.35pt"><p>Weight increased (Abnormal weight gain)</p></td><td style="height:42.5pt; vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">Weight increased (Abnormal weight gain)</p></td><td style="height:42.5pt; vertical-align:top; width:79.35pt"><p style="margin-left:1.4pt; margin-right:0in">&nbsp;</p></td></tr></tbody></table><p style="margin-left:7.1pt; text-indent:-7.1pt"><sup>a&nbsp;&nbsp; </sup>Infant/toddlers (28&nbsp;days to 23&nbsp;months): two Grade&nbsp;4 Neutrophil count decreased (Neutropenia) reactions reported. Grade&nbsp;3 reactions included seven cases of Neutrophil count decreased (Neutropenia), three cases of Anaemia, three cases of Weight increased (Abnormal weight gain), and one case each of ALT increased and Vomiting.</p><p style="margin-left:7.1pt; text-indent:-7.1pt"><sup>b</sup>&nbsp; Children (2&nbsp;to&nbsp;11&nbsp;years): no Grade&nbsp;4 reactions were reported. Three reported Grade&nbsp;3 cases of Neutrophil count decreased (Neutropenia), and one case each of Paraesthesia and Myalgia.</p><p style="margin-left:7.1pt; text-indent:-7.1pt"><sup>c</sup>&nbsp; Adolescents (12&nbsp;to &lt;18&nbsp;years): no Grades&nbsp;3 and 4 reactions were reported.</p><p>Description of selected adverse reactions</p><p>&nbsp;</p><p>Neurologic reactions</p><p>In the overall safety database (n=196), the maximum grade neurologic reaction observed was Grade&nbsp;3 which was observed in five (3%) patients and included dizziness (two patients, 1%), paraesthesia (two patients, 1%), and gait disturbance (one patient, &lt;1%). The overall incidence was 26% for dizziness, 8% for paraesthesia and 4% for gait disturbance. Neurologic reactions leading to dose modification included dizziness (2%), paraesthesia (1%), and gait disturbance (&lt;1%). One patient permanently discontinued the treatment due to Grade&nbsp;3 gait disturbance. In all cases except of one, patients with evidence of anti‑tumour activity who required a dose reduction were able to continue dosing at a reduced dose and/or schedule (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Transaminase elevations</p><p>In the overall safety database (n=196), the maximum grade transaminase elevation observed was Grade&nbsp;4 ALT increase in 2&nbsp;patients (1%) and AST increase in 1&nbsp;patient (&lt;1%). Grade&nbsp;3 ALT and AST increases in 4 (2%) and 2 (1%) of patients, respectively. Majority of Grade&nbsp;3 elevations were transient appearing in the first or second month of treatment and resolving to Grade&nbsp;1 by months 3‑4. Grade&nbsp;2 ALT and AST increases were observed in 10 (5%) and 8 (4%) of patients, respectively, and Grade&nbsp;1 ALT and AST increases were observed in 47 (24%) and 41 (21%) of patients, respectively.</p><p>ALT and AST increases leading to dose modifications occurred in 10 (5%) patients and 8 (4%) patients, respectively (see section&nbsp;4.4). No patient permanently discontinued the treatment due to Grade&nbsp;3‑4 ALT and AST increases.</p><p>&nbsp;</p><p>Additional information on special populations&nbsp;</p><p>&nbsp;</p><p>Paediatric patients</p><p>Of the 196&nbsp;patients treated with VITRAKVI, 73 (37%) patients were from 28&nbsp;days to 18&nbsp;years of age. Of these 73&nbsp;patients, 40% were 28&nbsp;days to &lt;&nbsp;2&nbsp;years (n=29), 41% were 2&nbsp;years to &lt;&nbsp;12&nbsp;years (n=30), and 19% were 12&nbsp;years to &lt;&nbsp;18&nbsp;years (n=14). The safety profile in the paediatric population (&lt;&nbsp;18&nbsp;years) was consistent in types of reported adverse reactions to those observed in the adult population. The majority of adverse reactions were Grade&nbsp;1 or 2 in severity (see Table&nbsp;3) and were resolved without VITRAKVI dose modification or discontinuation. The adverse reactions of vomiting (38% versus 15% in adults), leucocyte count decrease (16% versus 11% in adults), neutrophil count decrease (27% versus 7% in adults), and blood alkaline phosphatase increased (12% versus 4% in adults) were more frequent in paediatric patients compared to adults.</p><p>&nbsp;</p><p>Elderly</p><p>Of the 196&nbsp;patients in the overall safety population who received VITRAKVI, 35 (18%) patients were 65&nbsp;years or older and 10 (5%) patients were 75&nbsp;years or older. The safety profile in elderly patients (&ge;&nbsp;65&nbsp;years) is consistent with that seen in younger patients. The adverse reaction gait disturbance (11% versus 5% in all adults) was more frequent in patients of 65&nbsp;years or older.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>The National Pharmacovigilance Centre (NPC).</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is limited experience of overdose with VITRAKVI. Symptoms of overdose are not established. In the event of overdose, physicians should follow general supportive measures and treat symptomatically.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0in; margin-right:0in; text-indent:0in">Pharmacotherapeutic group: Antineoplastic and immunomodulating agents, antineoplastic agents, protein kinase inhibitors, ATC code: L01XE53.</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">Mechanism of action</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p><p>Larotrectinib is an adenosine triphosphate (ATP)‑competitive and selective tropomyosin receptor kinase (TRK) inhibitor that was rationally designed to avoid activity with off‑target kinases. The target for larotrectinib is the TRK family of proteins inclusive of TRKA, TRKB, and TRKC that are encoded by <em>NTRK1</em>, <em>NTRK2</em> and <em>NTRK3</em> genes, respectively. In a broad panel of purified enzyme assays, larotrectinib inhibited TRKA, TRKB, and TRKC with IC<sub>50</sub> values between 5‑11&nbsp;nM. The only other kinase activity occurred at 100‑fold higher concentrations. In <em>in vitro </em>and<em> in vivo</em> tumour models, larotrectinib demonstrated anti‑tumour activity in cells with constitutive activation of TRK proteins resulting from gene fusions, deletion of a protein regulatory domain, or in cells with TRK protein overexpression.</p><p>&nbsp;</p><p>In‑frame gene fusion events resulting from chromosomal rearrangements of the human genes <em>NTRK1</em>, <em>NTRK2</em>, and <em>NTRK3</em> lead to the formation of oncogenic TRK fusion proteins. These resultant novel chimeric oncogenic proteins are aberrantly expressed, driving constitutive kinase activity subsequently activating downstream cell signalling pathways involved in cell proliferation and survival leading to TRK fusion‑positive cancer.</p><p>&nbsp;</p><p>Acquired resistance mutations after progression on TRK inhibitors have been observed. Larotrectinib had minimal activity in cell lines with point mutations in the TRKA kinase domain, including the clinically identified acquired resistance mutation, G595R. Point mutations in the TRKC kinase domain with clinically identified acquired resistance to larotrectinib include G623R, G696A, and F617L.</p><p>&nbsp;</p><p>The molecular causes for primary resistance to larotrectinib are not known. It is therefore not known if the presence of a concomitant oncogenic driver in addition to an <em>NTRK</em> gene fusion affects the efficacy of TRK inhibition. The measured impact of any concomitant genomic alterations on larotrectinib efficacy is provided below (see clinical efficacy).</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">Pharmacodynamic effect</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p><p>Cardiac electrophysiology</p><p>In 36&nbsp;healthy adult subjects receiving single doses ranging from 100&nbsp;mg to 900&nbsp;mg, VITRAKVI did not prolong the QT interval to any clinically relevant extent.</p><p>The 200&nbsp;mg dose corresponds to a peak exposure (C<sub>max</sub>) similar to that observed with larotrectinib 100&nbsp;mg BID at steady state. A shortening of QTcF was observed with VITRAKVI dosing, with a maximum mean effect observed between 3&nbsp;and 24&nbsp;hours after C<sub>max</sub>, with a geometric mean decrease in QTcF from baseline of ‑13.2&nbsp;msec (range ‑10&nbsp;to&nbsp;‑15.6&nbsp;msec). Clinical relevance of this finding has not been established.</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">Clinical efficacy</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p><p>Overview of studies</p><p>The efficacy and safety of VITRAKVI were studied in three multicentre, open‑label, single‑arm clinical studies in adult and paediatric cancer patients (Table&nbsp;4). The studies are still ongoing.</p><p>Patients with and without documented <em>NTRK</em> gene fusion were allowed to participate in Study&nbsp;1 and Study&nbsp;3 (&ldquo;SCOUT&rdquo;). Patients enrolled to Study&nbsp;2 (&ldquo;NAVIGATE&rdquo;) were required to have TRK fusion‑positive cancer. The pooled primary analysis set of efficacy includes 164&nbsp;patients with TRK fusion‑positive cancer enrolled across the three studies that had measurable disease assessed by RECIST v1.1, a non‑CNS primary tumour and received at least one dose of larotrectinib as of July 2019. These patients were required to have received prior standard therapy appropriate for their tumour type and stage of disease or who, in the opinion of the investigator, would have had to undergo radical surgery (such as limb amputation, facial resection, or paralysis causing procedure), or were unlikely to tolerate, or derive clinically meaningful benefit from available standard of care therapies in the advanced disease setting. The major efficacy outcome measures were overall response rate (ORR) and duration of response (DOR), as determined by a blinded independent review committee (BIRC).</p><p>In addition, 24&nbsp;patients with primary CNS tumours and measurable disease at baseline were treated in Study&nbsp;2 (&ldquo;NAVIGATE&rdquo;) and in Study&nbsp;3 (&ldquo;SCOUT&rdquo;). All primary CNS tumour patients had received prior cancer treatment (surgery, radiotherapy and/or previous systemic therapy). Tumour responses were assessed by the investigator using RANO or RECIST v1.1 criteria.</p><p>&nbsp;</p><p>Identification of <em>NTRK</em> gene fusions relied upon the molecular test methods: next generation sequencing (NGS) used in 166&nbsp;patients, reverse transcription‑polymerase chain reaction (RT‑PCR) used in 9&nbsp;patients, fluorescence <em>in situ</em> hybridization (FISH) used in 12&nbsp;patients, and Nanostring in 1&nbsp;patient as routinely performed at certified laboratories.</p><p>Table&nbsp;4: Clinical studies contributing to the efficacy analyses in solid and primary CNS tumours</p><table cellspacing="0" cellpadding="0" border="1" style="width:595px"><tbody><tr><td style="vertical-align:top; width:184.3pt"><p>Study name, design and patient population</p></td><td style="vertical-align:top; width:106.3pt"><p>Dose and formulation</p></td><td style="vertical-align:top; width:134.65pt"><p>Tumour types included in efficacy analysis</p></td><td style="vertical-align:top; width:21.3pt"><p style="text-align:center">n</p></td></tr><tr><td style="vertical-align:top; width:184.3pt"><p><strong>Study&nbsp;1</strong></p><p>NCT02122913</p><p>&nbsp;</p><p style="margin-left:8.55pt; margin-right:0in; text-indent:-7.1pt"><!--[if !supportLists]-->&bull;&nbsp; <!--[endif]-->Phase&nbsp;1, open‑label, dose escalation and expansion study; expansion phase required tumours with an <em>NTRK</em> gene fusion</p><p style="margin-left:8.55pt; margin-right:0in; text-indent:-7.1pt"><!--[if !supportLists]-->&bull;&nbsp; <!--[endif]-->Adult patients (&ge;&nbsp;18&nbsp;years) with advanced solid tumours with an <em>NTRK</em> gene fusion</p></td><td style="vertical-align:top; width:106.3pt"><p>Doses up to 200&nbsp;mg once or twice daily (25&nbsp;mg, 100&nbsp;mg capsules or 20&nbsp;mg/mL oral solution)</p></td><td style="vertical-align:top; width:134.65pt"><p>Thyroid (n=4)</p><p>Salivary gland (n=3)</p><p>GIST (n=2)a</p><p>Soft tissue sarcoma (n=2)</p><p>NSCLC (n=1)<sup>b,</sup> <sup>c</sup></p><p>Unknown primary cancer (n=1)</p></td><td style="vertical-align:top; width:21.3pt"><p style="text-align:center">13</p></td></tr><tr><td style="vertical-align:top; width:184.3pt"><p><strong>Study&nbsp;2</strong> &ldquo;NAVIGATE&rdquo;</p><p>NCT02576431</p><p>&nbsp;</p><p style="margin-left:8.55pt; margin-right:0in; text-indent:-7.1pt"><!--[if !supportLists]-->&bull;&nbsp; <!--[endif]-->Phase&nbsp;2 multinational, open label, tumour &ldquo;basket&rdquo; study</p><p style="margin-left:8.55pt; margin-right:0in; text-indent:-7.1pt"><!--[if !supportLists]-->&bull;&nbsp; <!--[endif]-->Adult and paediatric patients &ge;&nbsp;12&nbsp;years with advanced solid tumours with an <em>NTRK</em> gene fusion</p></td><td style="vertical-align:top; width:106.3pt"><p>100&nbsp;mg twice daily (25&nbsp;mg, 100&nbsp;mg capsules or 20&nbsp;mg/mL oral solution)</p></td><td style="vertical-align:top; width:134.65pt"><p>Thyroid (n=23)b</p><p>Salivary gland (n=18)</p><p>Soft tissue sarcoma (n=16)</p><p>NSCLC (n=11)<sup>b, c</sup></p><p>Colorectal (n=8)</p><p>Primary CNS (n=7)</p><p>Melanoma (n=6)</p><p>Breast, non‑secretory (n=3)</p><p>Breast, secretory (n=2)</p><p>GIST (n=2)<sup>a</sup></p><p>Biliary (n=2)</p><p>Pancreas (n=2)</p><p>SCLC (n=1)<sup>b, d</sup></p><p>Appendix (n=1)</p><p>Bone sarcoma (n=1)</p><p>Hepatic<sup>e</sup> (n=1)</p><p>Prostate (n=1)</p></td><td style="vertical-align:top; width:21.3pt"><p style="text-align:center">105</p></td></tr><tr><td style="vertical-align:top; width:184.3pt"><p><strong>Study&nbsp;3</strong> &ldquo;SCOUT&rdquo;</p><p>NCT02637687</p><p>&nbsp;</p><p style="margin-left:8.55pt; margin-right:0in; text-indent:-7.1pt"><!--[if !supportLists]-->&bull;&nbsp; <!--[endif]-->Phase&nbsp;1/2 multinational, open‑label, dose escalation and expansion study; Phase&nbsp;2 expansion cohort required advanced solid tumours with an <em>NTRK</em> gene fusion, including locally advanced infantile fibrosarcoma</p><p style="margin-left:8.55pt; margin-right:0in; text-indent:-7.1pt"><!--[if !supportLists]-->&bull;&nbsp; <!--[endif]-->Paediatric patients &ge;&nbsp;1&nbsp;month to 21&nbsp;years with advanced cancer or with primary CNS tumours</p></td><td style="vertical-align:top; width:106.3pt"><p>Doses up to 100&nbsp;mg/m<sup>2 </sup>twice daily (25&nbsp;mg, 100&nbsp;mg capsules or 20&nbsp;mg/mL oral solution)</p></td><td style="vertical-align:top; width:134.65pt"><p>Infantile fibrosarcoma (n=32)</p><p>Soft tissue sarcoma (n=18)</p><p>Primary CNS (n=17)</p><p>Bone sarcoma (n=1)</p><p>Congenital mesoblastic nephroma (n=1)</p><p>Melanoma (n=1)</p></td><td style="vertical-align:top; width:21.3pt"><p style="text-align:center">70</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:425.25pt"><p>Total number of patients (n)<sup>*</sup></p></td><td style="vertical-align:top; width:21.3pt"><p style="text-align:center">188</p></td></tr></tbody></table><p style="margin-left:7.1pt; margin-right:0in; text-indent:-7.1pt">*&nbsp;&nbsp; consist of 164&nbsp;patients with IRC tumour response assessment and 24&nbsp;patients with primary CNS tumours (including astrocytoma, glioblastoma, glioma, glioneuronal tumours, neuronal and mixed neuronal‑glial tumours, and primitive neuro‑ectodermal tumour) with investigator tumour response assessment</p><p style="margin-left:7.1pt; margin-right:0in; text-indent:-7.1pt">a&nbsp;&nbsp; GIST: gastrointestinal stromal tumour</p><p style="margin-left:7.1pt; margin-right:0in; text-indent:-7.1pt">b&nbsp;&nbsp; brain metastases observed in 6&nbsp;NSCLC, 4&nbsp;thyroid, 2&nbsp;melanoma, 1&nbsp;SCLC patient, and 1&nbsp;breast (non‑secretory) patient</p><p style="margin-left:7.1pt; margin-right:0in; text-indent:-7.1pt"><sup>c&nbsp;&nbsp; </sup>NSCLC: non‑small cell lung cancer</p><p style="margin-left:7.1pt; margin-right:0in; text-indent:-7.1pt">d&nbsp;&nbsp; SCLC: small cell lung cancer</p><p style="margin-left:7.1pt; margin-right:0in; text-indent:-7.1pt"><sup>e&nbsp;&nbsp; </sup>hepatocellular carcinoma</p><p>&nbsp;</p><p>Baseline characteristics for the pooled 164&nbsp;patients with solid tumours with an <em>NTRK</em> gene fusion were as follows: median age 42&nbsp;years (range 0.1‑84&nbsp;years); 34% &lt;&nbsp;18&nbsp;years of age, and 66% &ge;&nbsp;18&nbsp;years; 77% white and 49% male; and ECOG PS 0‑1 (86%), 2 (12%), or 3 (2%). Ninety‑four percent of patients had received prior treatment for their cancer, defined as surgery, radiotherapy, or systemic therapy. Of these, 77% had received prior systemic therapy with a median of 1&nbsp;prior systemic</p><p>treatment regimen. Twenty‑two percent of all patients had received no prior systemic therapy. Of those 164&nbsp;patients the most common tumour types represented were soft tissue sarcoma (22%), infantile fibrosarcoma (20%), thyroid cancer (16%), salivary gland tumour (13%), and lung cancer (8%).</p><p>Baseline characteristics for the 24&nbsp;patients with primary CNS tumours with an <em>NTRK</em> gene fusion assessed by investigator were as follows: median age 8&nbsp;years (range 1.3‑79&nbsp;years); 20&nbsp;patients &lt;&nbsp;18&nbsp;years of age, and 4&nbsp;patients &ge;&nbsp;18&nbsp;years, and 19&nbsp;patients white and 11&nbsp;patients male; and ECOG PS 0‑1 (22&nbsp;patients), or 2 (1&nbsp;patient). All patients had received prior treatment for their cancer, defined as surgery, radiotherapy, or systemic therapy. There was a median of 1&nbsp;prior systemic treatment regimen received.</p><p>&nbsp;</p><p>Efficacy results</p><p>The pooled efficacy results for overall response rate, duration of response and time to first response, in the primary analysis population (n=164) and with post‑hoc addition of primary CNS tumours (n=24) resulting in the pooled population (n=188), are presented in Table&nbsp;5 and Table&nbsp;6.</p><p>&nbsp;</p><p>Table&nbsp;5: Pooled efficacy results in solid tumours including and excluding primary CNS tumours</p><table cellspacing="0" cellpadding="0" border="1" style="width:605px"><tbody><tr><td style="vertical-align:top; width:198.45pt"><p>Efficacy parameter</p></td><td style="vertical-align:top; width:127.6pt"><p style="text-align:left">Analysis in solid</p><p style="text-align:left">tumours excluding</p><p style="text-align:left">primary CNS tumours</p><p style="text-align:left">(n=164)<sup>a</sup></p></td><td style="vertical-align:top; width:127.55pt"><p style="margin-left:6.6pt; margin-right:0in; text-align:left">Analysis in solid</p><p style="margin-left:6.6pt; margin-right:0in; text-align:left">tumours including</p><p style="margin-left:6.6pt; margin-right:0in; text-align:left">primary CNS tumours</p><p style="margin-left:6.6pt; margin-right:0in; text-align:left">(n=188)<sup>a, b</sup></p></td></tr><tr><td style="vertical-align:top; width:198.45pt"><p>Overall response rate (ORR) % (n)</p><p>[95% CI]</p></td><td style="vertical-align:top; width:127.6pt"><p style="text-align:left">73% (119)</p><p style="text-align:left">[65, 79]</p></td><td style="vertical-align:top; width:127.55pt"><p style="margin-left:6.6pt; margin-right:0in; text-align:left">66% (124)</p><p style="margin-left:6.6pt; margin-right:0in; text-align:left">[59, 73]</p></td></tr><tr><td style="vertical-align:top; width:198.45pt"><p>Complete response (CR)</p></td><td style="vertical-align:top; width:127.6pt"><p style="text-align:left">19% (31)</p></td><td style="vertical-align:top; width:127.55pt"><p style="margin-left:6.6pt; margin-right:0in; text-align:left">18% (33)</p></td></tr><tr><td style="vertical-align:top; width:198.45pt"><p>Pathological complete responsec</p></td><td style="vertical-align:top; width:127.6pt"><p style="text-align:left">5% (8)</p></td><td style="vertical-align:top; width:127.55pt"><p style="margin-left:6.6pt; margin-right:0in; text-align:left">4% (8)</p></td></tr><tr><td style="vertical-align:top; width:198.45pt"><p>Partial response (PR)</p></td><td style="vertical-align:top; width:127.6pt"><p style="text-align:left">49% (80)</p></td><td style="vertical-align:top; width:127.55pt"><p style="margin-left:6.6pt; margin-right:0in; text-align:left">44% (83)<sup>d</sup></p></td></tr><tr><td style="vertical-align:top; width:198.45pt"><p>Time to first response (median, months) [range]</p></td><td style="vertical-align:top; width:127.6pt"><p style="text-align:left">1.84</p><p style="text-align:left">[0.92, 14.55]</p></td><td style="vertical-align:top; width:127.55pt"><p style="margin-left:6.6pt; margin-right:0in; text-align:left">1.84</p><p style="margin-left:6.6pt; margin-right:0in; text-align:left">[0.92, 14.55]</p></td></tr><tr><td style="height:36.85pt; vertical-align:top; width:198.45pt"><p>Duration of response (median, months)</p><p>[range]</p><p>% with duration &ge;&nbsp;12&nbsp;months</p><p>% with duration &ge;&nbsp;24&nbsp;months</p></td><td style="height:36.85pt; vertical-align:top; width:127.6pt"><p style="text-align:left">NR</p><p style="text-align:left">[0.0+, 50.6+]</p><p style="text-align:left">76%</p><p style="text-align:left">67%</p></td><td style="height:36.85pt; vertical-align:top; width:127.55pt"><p style="margin-left:6.6pt; margin-right:0in; text-align:left">NR</p><p style="margin-left:6.6pt; margin-right:0in; text-align:left">[0.0+, 50.6+]</p><p style="margin-left:6.6pt; margin-right:0in; text-align:left">74%</p><p style="margin-left:6.6pt; margin-right:0in; text-align:left">65%</p></td></tr></tbody></table><p>NR: not reached</p><p>+ denotes ongoing</p><p style="margin-left:7.1pt; margin-right:0in; text-indent:-7.1pt">a&nbsp;&nbsp; Independent review committee analysis by RECIST v1.1 for solid tumours except primary CNS tumours (164&nbsp;patients).</p><p style="margin-left:7.1pt; margin-right:0in; text-indent:-7.1pt">b&nbsp;&nbsp; Investigator assessment using either RANO or RECIST v1.1 criteria for primary CNS tumours (24&nbsp;patients).</p><p style="margin-left:7.1pt; margin-right:0in; text-indent:-7.1pt">c&nbsp;&nbsp; A pathological CR was a CR achieved by patients who were treated with larotrectinib and subsequently underwent surgical resection with no viable tumour cells and negative margins on post‑surgical pathology evaluation. The pre‑surgical best response for these patients was reclassified pathological CR after surgery following RECIST v.1.1.</p><p style="margin-left:7.1pt; margin-right:0in; text-indent:-7.1pt"><sup>d</sup>&nbsp; An additional 1% (2&nbsp;patients with primary CNS tumours) had partial responses, pending confirmation.</p><p style="margin-left:89.85pt; margin-right:0in; text-indent:-89.85pt">Table&nbsp;6: Overall response rate and duration of response by tumour type</p><table cellspacing="0" cellpadding="0" border="1" style="width:612px"><tbody><tr><td rowspan="3" style="height:9.2pt; width:107.7pt"><p><strong>Tumour type</strong></p></td><td rowspan="3" style="height:9.2pt; width:49.55pt"><p style="text-align:center"><strong>Patients (n=188)</strong></p></td><td colspan="2" style="height:9.2pt; width:134.7pt"><p style="text-align:center"><strong>ORR</strong></p></td><td colspan="3" style="height:9.2pt; vertical-align:top; width:167.05pt"><p style="text-align:center"><strong>DOR</strong></p></td></tr><tr><td rowspan="2" style="height:9.2pt; width:56.75pt"><p style="text-align:center"><strong>%</strong></p></td><td rowspan="2" style="height:9.2pt; width:77.95pt"><p style="text-align:center"><strong>95% CI</strong></p></td><td colspan="2" style="height:9.2pt; width:82.0pt"><p style="text-align:center"><strong>months</strong></p></td><td rowspan="2" style="height:9.2pt; vertical-align:top; width:85.05pt"><p style="text-align:center"><strong>Range (months)</strong></p></td></tr><tr><td style="height:9.2pt; width:39.5pt"><p style="text-align:center">&ge;<strong>&nbsp;12</strong></p></td><td style="height:9.2pt; width:42.5pt"><p style="text-align:center">&ge;<strong>&nbsp;24</strong></p></td></tr><tr><td style="height:17.95pt; width:107.7pt"><p>Soft tissue sarcoma<sup>a</sup></p></td><td style="height:17.95pt; width:49.55pt"><p style="text-align:center">36</p></td><td style="height:17.95pt; width:56.75pt"><p style="text-align:center">81%</p></td><td style="height:17.95pt; width:77.95pt"><p style="text-align:center">64%, 92%</p></td><td style="height:17.95pt; width:39.5pt"><p style="text-align:center">69%</p></td><td style="height:17.95pt; width:42.5pt"><p style="text-align:center">69%</p></td><td style="height:17.95pt; width:85.05pt"><p style="text-align:center">0.0+, 50.6+</p></td></tr><tr><td style="height:.2in; width:107.7pt"><p>Infantile fibrosarcoma<sup>a</sup></p></td><td style="height:.2in; width:49.55pt"><p style="text-align:center">32</p></td><td style="height:.2in; width:56.75pt"><p style="text-align:center">97%</p></td><td style="height:.2in; width:77.95pt"><p style="text-align:center">84%, 100%</p></td><td style="height:.2in; width:39.5pt"><p style="text-align:center">72%</p></td><td style="height:.2in; width:42.5pt"><p style="text-align:center">63%</p></td><td style="height:.2in; width:85.05pt"><p style="text-align:center">1.6+, 28.6+</p></td></tr><tr><td style="height:.2in; width:107.7pt"><p>Thyroid<sup>a</sup></p></td><td style="height:.2in; width:49.55pt"><p style="text-align:center">27</p></td><td style="height:.2in; width:56.75pt"><p style="text-align:center">56%</p></td><td style="height:.2in; width:77.95pt"><p style="text-align:center">35%, 75%</p></td><td style="height:.2in; width:39.5pt"><p style="text-align:center">93%</p></td><td style="height:.2in; width:42.5pt"><p style="text-align:center">58%</p></td><td style="height:.2in; width:85.05pt"><p style="text-align:center">3.7+, 32.9</p></td></tr><tr><td style="height:.2in; width:107.7pt"><p>Primary CNS<sup>b</sup></p></td><td style="height:.2in; width:49.55pt"><p style="text-align:center">24</p></td><td style="height:.2in; width:56.75pt"><p style="text-align:center">21%</p></td><td style="height:.2in; width:77.95pt"><p style="text-align:center">7%, 42%</p></td><td style="height:.2in; width:39.5pt"><p style="text-align:center">NR</p></td><td style="height:.2in; width:42.5pt"><p style="text-align:center">NR</p></td><td style="height:.2in; width:85.05pt"><p style="text-align:center">1.7+, 10.1+</p></td></tr><tr><td style="height:16.6pt; width:107.7pt"><p>Salivary gland<sup>a</sup></p></td><td style="height:16.6pt; width:49.55pt"><p style="text-align:center">21</p></td><td style="height:16.6pt; width:56.75pt"><p style="text-align:center">86%</p></td><td style="height:16.6pt; width:77.95pt"><p style="text-align:center">64%, 97%</p></td><td style="height:16.6pt; width:39.5pt"><p style="text-align:center">94%</p></td><td style="height:16.6pt; width:42.5pt"><p style="text-align:center">87%</p></td><td style="height:16.6pt; width:85.05pt"><p style="text-align:center">1.9+, 44.7+</p></td></tr><tr><td style="height:.2in; width:107.7pt"><p>Lung<sup>a</sup></p></td><td style="height:.2in; width:49.55pt"><p style="text-align:center">13</p></td><td style="height:.2in; width:56.75pt"><p style="text-align:center">77%</p></td><td style="height:.2in; width:77.95pt"><p style="text-align:center">46%, 95%</p></td><td style="height:.2in; width:39.5pt"><p style="text-align:center">62%</p></td><td style="height:.2in; width:42.5pt"><p style="text-align:center">62%</p></td><td style="height:.2in; width:85.05pt"><p style="text-align:center">3.7, 36.8+</p></td></tr><tr><td style="height:.2in; width:107.7pt"><p>Colon<sup>a</sup></p></td><td style="height:.2in; width:49.55pt"><p style="text-align:center">8</p></td><td style="height:.2in; width:56.75pt"><p style="text-align:center">38%</p></td><td style="height:.2in; width:77.95pt"><p style="text-align:center">9%, 76%</p></td><td style="height:.2in; width:39.5pt"><p style="text-align:center">50%</p></td><td style="height:.2in; width:42.5pt"><p style="text-align:center">NR</p></td><td style="height:.2in; width:85.05pt"><p style="text-align:center">5.4+, 20.7+</p></td></tr><tr><td style="height:.2in; width:107.7pt"><p>Melanoma<sup>a</sup></p></td><td style="height:.2in; width:49.55pt"><p style="text-align:center">7</p></td><td style="height:.2in; width:56.75pt"><p style="text-align:center">43%</p></td><td style="height:.2in; width:77.95pt"><p style="text-align:center">10%, 82%</p></td><td style="height:.2in; width:39.5pt"><p style="text-align:center">50%</p></td><td style="height:.2in; width:42.5pt"><p style="text-align:center">NR</p></td><td style="height:.2in; width:85.05pt"><p style="text-align:center">1.9+, 23.2+</p></td></tr><tr><td style="height:.2in; width:107.7pt"><p>Breast<sup>a, c</sup></p></td><td style="height:.2in; width:49.55pt"><p style="text-align:center">5</p></td><td style="height:.2in; width:56.75pt"><p style="text-align:center">60%</p></td><td style="height:.2in; width:77.95pt"><p style="text-align:center">15%, 95%</p></td><td style="height:.2in; width:39.5pt"><p style="text-align:center">NR</p></td><td style="height:.2in; width:42.5pt"><p style="text-align:center">NR</p></td><td style="height:.2in; width:85.05pt"><p style="text-align:center">5.6+, 9.2+</p></td></tr><tr><td style="height:.2in; width:107.7pt"><p>Gastrointestinal stromal tumour<sup>a</sup></p></td><td style="height:.2in; width:49.55pt"><p style="text-align:center">4</p></td><td style="height:.2in; width:56.75pt"><p style="text-align:center">100%</p></td><td style="height:.2in; width:77.95pt"><p style="text-align:center">40%, 100%</p></td><td style="height:.2in; width:39.5pt"><p style="text-align:center">75%</p></td><td style="height:.2in; width:42.5pt"><p style="text-align:center">38%</p></td><td style="height:.2in; width:85.05pt"><p style="text-align:center">9.5, 31.1+</p></td></tr><tr><td style="height:.2in; width:107.7pt"><p>Bone sarcoma<sup>a</sup></p></td><td style="height:.2in; width:49.55pt"><p style="text-align:center">2</p></td><td style="height:.2in; width:56.75pt"><p style="text-align:center">50%</p></td><td style="height:.2in; width:77.95pt"><p style="text-align:center">1%, 99%</p></td><td style="height:.2in; width:39.5pt"><p style="text-align:center">0%</p></td><td style="height:.2in; width:42.5pt"><p style="text-align:center">0%</p></td><td style="height:.2in; width:85.05pt"><p style="text-align:center">9.5</p></td></tr><tr><td style="height:.2in; width:107.7pt"><p>Cholangiocarcinoma<sup>a</sup></p></td><td style="height:.2in; width:49.55pt"><p style="text-align:center">2</p></td><td style="height:.2in; width:56.75pt"><p style="text-align:center">SD, NE</p></td><td style="height:.2in; width:77.95pt"><p style="text-align:center">NA</p></td><td style="height:.2in; width:39.5pt"><p style="text-align:center">NA</p></td><td style="height:.2in; width:42.5pt"><p style="text-align:center">NA</p></td><td style="height:.2in; width:85.05pt"><p style="text-align:center">NA</p></td></tr><tr><td style="height:.2in; width:107.7pt"><p>Pancreas<sup>a</sup></p></td><td style="height:.2in; width:49.55pt"><p style="text-align:center">2</p></td><td style="height:.2in; width:56.75pt"><p style="text-align:center">SD, SD</p></td><td style="height:.2in; width:77.95pt"><p style="text-align:center">NA</p></td><td style="height:.2in; width:39.5pt"><p style="text-align:center">NA</p></td><td style="height:.2in; width:42.5pt"><p style="text-align:center">NA</p></td><td style="height:.2in; width:85.05pt"><p style="text-align:center">NA</p></td></tr><tr><td style="height:.2in; width:107.7pt"><p>Congenital mesoblastic nephroma<sup>a</sup></p></td><td style="height:.2in; width:49.55pt"><p style="text-align:center">1</p></td><td style="height:.2in; width:56.75pt"><p style="text-align:center">100%</p></td><td style="height:.2in; width:77.95pt"><p style="text-align:center">3%, 100%</p></td><td style="height:.2in; width:39.5pt"><p style="text-align:center">100%</p></td><td style="height:.2in; width:42.5pt"><p style="text-align:center">NR</p></td><td style="height:.2in; width:85.05pt"><p style="text-align:center">20.8+</p></td></tr><tr><td style="height:.2in; width:107.7pt"><p>Unknown primary cancer</p></td><td style="height:.2in; width:49.55pt"><p style="text-align:center">1</p></td><td style="height:.2in; width:56.75pt"><p style="text-align:center">100%</p></td><td style="height:.2in; width:77.95pt"><p style="text-align:center">3%, 100%</p></td><td style="height:.2in; width:39.5pt"><p style="text-align:center">0%</p></td><td style="height:.2in; width:42.5pt"><p style="text-align:center">0%</p></td><td style="height:.2in; width:85.05pt"><p style="text-align:center">7.4</p></td></tr><tr><td style="height:.2in; width:107.7pt"><p>Appendix<sup>a</sup></p></td><td style="height:.2in; width:49.55pt"><p style="text-align:center">1</p></td><td style="height:.2in; width:56.75pt"><p style="text-align:center">SD</p></td><td style="height:.2in; width:77.95pt"><p style="text-align:center">NA</p></td><td style="height:.2in; width:39.5pt"><p style="text-align:center">NA</p></td><td style="height:.2in; width:42.5pt"><p style="text-align:center">NA</p></td><td style="height:.2in; width:85.05pt"><p style="text-align:center">NA</p></td></tr><tr><td style="height:.2in; width:107.7pt"><p>Hepatic</p></td><td style="height:.2in; width:49.55pt"><p style="text-align:center">1</p></td><td style="height:.2in; width:56.75pt"><p style="text-align:center">NE</p></td><td style="height:.2in; width:77.95pt"><p style="text-align:center">NA</p></td><td style="height:.2in; width:39.5pt"><p style="text-align:center">NA</p></td><td style="height:.2in; width:42.5pt"><p style="text-align:center">NA</p></td><td style="height:.2in; width:85.05pt"><p style="text-align:center">NA</p></td></tr><tr><td style="height:.2in; width:107.7pt"><p>Prostate</p></td><td style="height:.2in; width:49.55pt"><p style="text-align:center">1</p></td><td style="height:.2in; width:56.75pt"><p style="text-align:center">PD</p></td><td style="height:.2in; width:77.95pt"><p style="text-align:center">NA</p></td><td style="height:.2in; width:39.5pt"><p style="text-align:center">NA</p></td><td style="height:.2in; width:42.5pt"><p style="text-align:center">NA</p></td><td style="height:.2in; width:85.05pt"><p style="text-align:center">NA</p></td></tr></tbody></table><p>&nbsp;</p><p>DOR: duration of response</p><p>NA: not applicable due to small numbers or lack of response</p><p>NE: not evaluable</p><p>NR: not reached</p><p>PD: progressive disease</p><p>SD: stable disease</p><p>+&nbsp;denotes ongoing response</p><p style="margin-left:7.1pt; margin-right:0in; text-indent:-7.1pt">a&nbsp;&nbsp; independent review committee analysis by RECIST v1.1</p><p style="margin-left:7.1pt; margin-right:0in; text-indent:-7.1pt">b&nbsp;&nbsp; patients with a primary CNS tumour were evaluated per investigator assessment using either RANO or RECIST v1.1 criteria</p><p style="margin-left:7.1pt; margin-right:0in; text-indent:-7.1pt"><sup>c&nbsp;&nbsp; </sup>with 3&nbsp;patients having non‑secretory (1&nbsp;complete, 1&nbsp;partial responder and 1&nbsp;progressive disease) and 2&nbsp;patients having secretory breast cancer (1&nbsp;partial and 1&nbsp;stable disease)</p><p>&nbsp;</p><p>Due to the rarity of TRK fusion‑positive cancer, patients were studied across multiple tumour types with a limited number of patients in some tumour types, causing uncertainty in the ORR estimate per tumour type. The ORR in the total population may not reflect the expected response in a specific tumour type.</p><p>&nbsp;</p><p>In the adult sub‑population (n=109), the ORR was 63%. In the paediatric sub‑population (n=55), the ORR was 91%.</p><p>&nbsp;</p><p>In 165&nbsp;patients with wide molecular characterisation before larotrectinib treatment, the ORR in 79&nbsp;patients who had other genomic alterations in addition to <em>NTRK</em> gene fusion was 58%, and in 86&nbsp;patients without other genomic alterations ORR was 74%.</p><p><u>Pooled primary analysis set</u></p><p>&nbsp;</p><p>The pooled primary analysis set consisted of 164&nbsp;patients and did not include primary CNS tumours. Median time on treatment before disease progression was 14.7&nbsp;months (range: 0.10 to 51.6&nbsp;months) based on July 2019 cut‑off. Forty‑four percent of patients had received VITRAKVI for 12&nbsp;months or more and 21% had received VITRAKVI 24&nbsp;months or more, with follow‑up ongoing at the time of the analysis.</p><p>At the time of analysis, the median duration of response had not been reached, an estimated 76% [95% CI: 67, 85] of responses lasted 12&nbsp;months or longer, and 67% [95% CI: 55, 78] of responses lasted 24&nbsp;months or longer. Ninety percent (90%) [95% CI: 85, 95] of patients treated were alive one year after the start of therapy and 82% [95% CI: 75, 90] after two years with the median for overall survival not yet being reached. Median progression free survival was 33.4&nbsp;months at the time of the analysis, with a progression free survival rate of 66% [95% CI: 58, 74] after 1&nbsp;year and 58% [95% CI: 48, 67] after 2&nbsp;years.</p><p>The median change in tumour size in the pooled primary analysis set was a decrease of 68%.</p><p>&nbsp;</p><p><u>Patients with primary CNS tumours</u></p><p><u>&nbsp;</u></p><p>At the time of data cut‑off, of the 24&nbsp;patients with primary CNS tumours confirmed response was observed in 5&nbsp;patients (21%) with 2&nbsp;of the 24&nbsp;patients (8%) being complete responders and 3&nbsp;patients (12.5%) being partial responders. In 2&nbsp;additional patients (8%) a not yet confirmed partial response was observed. Further 15&nbsp;patients (63%) had stable disease. Two patients (8%) had progressive disease. At the time of data cut‑off, time on treatment ranged from 1.2&nbsp;to 21.4&nbsp;months and was ongoing in 15&nbsp;out of 24&nbsp;patients, with one of these patients receiving post‑progression treatment.</p><p>&nbsp;</p><p><u>Conditional approval</u></p><p>This medicinal product has been authorised under a so‑called &lsquo;conditional approval&rsquo; scheme. This means that further evidence on this medicinal product is awaited.</p><p>The European Medicines Agency will review new information on this medicinal product at least every year and this SmPC will be updated as necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In cancer patients given VITRAKVI capsules, peak plasma levels (Cmax) of larotrectinib were achieved at approximately 1&nbsp;hour after dosing. Half‑life (t<sub>&frac12;</sub>) is approximately 3&nbsp;hours and steady state is reached within 8&nbsp;days with a systemic accumulation of 1.6&nbsp;fold. At the recommended dose of 100&nbsp;mg taken twice daily, steady‑state arithmetic mean (&plusmn; standard deviation) Cmax and daily AUC in adults were 914&nbsp;&plusmn;&nbsp;445&nbsp;ng/mL and 5410&nbsp;&plusmn;&nbsp;3813&nbsp;ng*h/mL, respectively. <em>In vitro</em> studies indicate that larotrectinib is not a substrate for either OATP1B1 or OATP1B3.</p><p>&nbsp;</p><p>In vitro studies indicate that larotrectinib does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6 at clinically relevant concentrations and is unlikely to affect clearance of substrates of these CYPs.</p><p>In vitro studies indicate that larotrectinib does not inhibit the transporters BCRP, P‑gp, OAT1, OAT3, OCT1, OCT2, OATP1B3, BSEP, MATE1 and MATE2‑K at clinically relevant concentrations and is unlikely to affect clearance of substrates of these transporters.</p><p>&nbsp;</p><p>Absorption</p><p>&nbsp;</p><p>VITRAKVI is available as a capsule and oral solution formulation.</p><p>The mean absolute bioavailability of larotrectinib was 34% (range: 32% to 37%) following a single 100&nbsp;mg oral dose. In healthy adult subjects, the AUC of larotrectinib in the oral solution formulation was similar to the capsule, with Cmax 36% higher with the oral solution formulation.</p><p>Larotrectinib Cmax was reduced by approximately 35% and there was no effect on AUC in healthy subjects administered VITRAKVI after a high‑fat and high‑calorie meal compared to the Cmax and AUC after overnight fasting.</p><p><em>Effect of gastric pH‑elevating agents on larotrectinib</em></p><p>Larotrectinib has pH‑dependent solubility. In vitro studies show that in liquid volumes relevant to the gastrointestinal (GI) tract larotrectinib is fully soluble over entire pH range of the GI tract. Therefore, larotrectinib is unlikely to be affected by pH‑modifying agents.</p><p>&nbsp;</p><p>Distribution</p><p>&nbsp;</p><p>The mean volume of distribution of larotrectinib in healthy adult subjects was 48&nbsp;L following intravenous administration of an IV microtracer in conjunction with a 100&nbsp;mg oral dose. Binding of larotrectinib to human plasma proteins in vitro was approximately 70% and was independent of drug concentration. The blood‑to‑plasma concentration ratio was approximately 0.9.</p><p>&nbsp;</p><p>Biotransformation</p><p>&nbsp;</p><p>Larotrectinib was metabolised predominantly by CYP3A4/5 <em>in vitro</em>. Following oral administration of a single 100&nbsp;mg dose of radiolabeled larotrectinib to healthy adult subjects, unchanged larotrectinib (19%) and an O‑glucuronide that is formed following loss of the hydroxypyrrolidine‑urea moiety (26%) were the major circulating radioactive drug components.</p><p>&nbsp;</p><p>Elimination</p><p>&nbsp;</p><p>The half‑life of larotrectinib in plasma of cancer patients given 100&nbsp;mg twice daily of VITRAKVI was approximately 3&nbsp;hours. Mean clearance (CL) of larotrectinib was approximately 34&nbsp;L/h following intravenous administration of an IV microtracer in conjunction with a&nbsp;100&nbsp;mg oral dose of VITRAKVI.</p><p>&nbsp;</p><p>Excretion</p><p>&nbsp;</p><p>Following oral administration of 100&nbsp;mg radiolabeled larotrectinib to healthy adult subjects, 58% of the administered radioactivity was recovered in faeces and 39% was recovered in urine and when an IV microtracer dose was given in conjunction with a 100&nbsp;mg oral dose of larotrectinib, 35% of the administered radioactivity was recovered in faeces and 53% was recovered in urine. The fraction excreted as unchanged drug in urine was 29% following IV microtracer dose, indicating that direct renal excretion accounted for 29% of total clearance.</p><p>&nbsp;</p><p>Linearity / non‑linearity</p><p>&nbsp;</p><p>The area under the plasma concentration‑time curve (AUC) and maximum plasma concentration (C<sub>max</sub>) of larotrectinib after a single dose in healthy adult subjects were dose proportional up to 400&nbsp;mg and slightly greater than proportional at doses of 600 to 900&nbsp;mg.</p><p>&nbsp;</p><p>Special populations</p><p>&nbsp;</p><p>Paediatric patients</p><p>Based on population pharmacokinetic analyses exposure (Cmax and AUC) in paediatric patients (1&nbsp;month to &lt;3&nbsp;months of age) at the recommended dose of 100&nbsp;mg/m2 with a maximum of 100&nbsp;mg BID was 3‑fold higher than in adults (&ge;18&nbsp;years of age) given the dose of 100&nbsp;mg&nbsp;BID. At the recommended dose, the C<sub>max</sub> in paediatric patients (&ge;3&nbsp;months to &lt;12&nbsp;years of age) was higher than in adults, but the AUC was similar to that in adults. For paediatric patients older than 12&nbsp;years of age, the recommended dose is likely to give similar Cmax and AUC as observed in adults.</p><p>Data defining exposure in small children (1&nbsp;month to &lt;6&nbsp;years of age) at the recommended dose is limited (n=33).</p><p>&nbsp;</p><p>Elderly</p><p>There are limited data in elderly. PK data is available only in 2&nbsp;patients over 65&nbsp;years.</p><p>Patients with hepatic impairment</p><p>A pharmacokinetic study was conducted in subjects with mild (Child‑Pugh&nbsp;A), moderate (Child‑Pugh&nbsp;B) and severe (Child‑Pugh&nbsp;C) hepatic impairment, and in healthy adult control subjects with normal hepatic function matched for age, body mass index and sex. All subjects received a single 100&nbsp;mg dose of larotrectinib. An increase in larotrectinib AUC0‑inf was observed in subjects with mild, moderate and severe hepatic impairment of 1.3, 2 and 3.2‑fold respectively versus those with normal hepatic function. Cmax was observed to increase slightly by 1.1, 1.1 and 1.5‑fold respectively.</p><p>&nbsp;</p><p>Patients with renal impairment</p><p>A pharmacokinetic study was conducted in subjects with end stage renal disease requiring dialysis, and in healthy adult control subjects with normal renal function matched for age, body mass index and sex. All subjects received a single 100&nbsp;mg dose of larotrectinib. An increase in larotrectinib Cmax and AUC0‑inf, of 1.25 and 1.46‑fold respectively was observed in renally impaired subjects versus those with normal renal function.</p><p>&nbsp;</p><p>Other special populations</p><p>Gender did not appear to influence larotrectinib pharmacokinetics to a clinically significant extent. There was not enough data to investigate the potential influence of race on the systemic exposure of larotrectinib.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Systemic toxicity</u></p><p>&nbsp;</p><p>Systemic toxicity was assessed in studies with daily oral administration up to 3&nbsp;months in rats and monkeys. Dose limiting skin lesions were only seen in rats and were primarily responsible for mortality and morbidity. Skin lesions were not seen in monkeys.</p><p>Clinical signs of gastrointestinal toxicity were dose limiting in monkeys. In rats, severe toxicity (STD10) was observed at doses corresponding to 1‑ to 2‑times the human AUC at the recommended clinical dose. No relevant systemic toxicity was observed in monkeys at doses which correspond to &gt;&nbsp;10‑times the human AUC at the recommended clinical dose.</p><p>&nbsp;</p><p>Embryotoxicity / Teratogenicity&nbsp;</p><p>&nbsp;</p><p>Larotrectinib was not teratogenic and embryotoxic when dosed daily during the period of organogenesis to pregnant rats and rabbits at maternotoxic doses, i.e. corresponding to 32‑times (rats) and 16‑times (rabbits) the human AUC at the recommended clinical dose. Larotrectinib crosses the placenta in both species.</p><p>&nbsp;</p><p>Reproduction toxicity</p><p>&nbsp;</p><p>Fertility studies with larotrectinib have not been conducted. In 3‑months toxicity studies, larotrectinib had no histological effect on the male reproductive organs in rats and monkeys at the highest tested doses corresponding to approximately 7‑times (male rats) and 10‑times (male monkeys) the human AUC at the recommended clinical dose. In addition, larotrectinib had no effect on spermatogenesis in rats.</p><p>&nbsp;</p><p>In a 1‑month repeat‑dose study in rats, fewer corpora lutea, increased incidence of anestrus and decreased uterine weight with uterine atrophy were observed and these effects were reversible. No effects on female reproductive organs were seen in the 3‑months toxicity studies in rats and monkeys at doses corresponding to approximately 3‑times (female rats) and 17‑times (female monkeys) the human AUC at the recommended clinical dose.</p><p>Larotrectinib was administered to juvenile rats from postnatal day (PND) 7&nbsp;to&nbsp;70. Pre‑weaning mortality (before PND&nbsp;21) was observed at the high dose level corresponding to 2.5‑ to 4‑times the AUC at the recommended dose. Growth and nervous system effects were seen at 0.5‑ to 4‑times the AUC at the recommended dose. Body weight gain was decreased in pre‑weaning male and female pups, with a post‑weaning increase in females at the end of exposure whereas reduced body weight gain was seen in males also post‑weaning without recovery. The male growth reduction was associated with delayed puberty. Nervous system effects (i.e. altered hindlimb functionality and, likely, increases in eyelid closure) demonstrated partial recovery. A decrease in pregnancy rate was also reported despite normal mating at the high‑dose level.</p><p>&nbsp;</p><p>Genotoxicity and carcinogenicity</p><p>&nbsp;</p><p>Carcinogenicity studies have not been performed with larotrectinib.</p><p>Larotrectinib was not mutagenic in bacterial reverse mutation (Ames) assays and in <em>in vitro</em> mammalian mutagenesis assays. Larotrectinib was negative in the <em>in vivo</em> mouse micronucleus test at the maximum tolerated dose of 500&nbsp;mg/kg.</p><p>&nbsp;</p><p>Safety pharmacology</p><p>&nbsp;</p><p>The safety pharmacology of larotrectinib was evaluated in several <em>in vitro</em> and <em>in vivo</em> studies that assessed effects on the CV, CNS, respiratory, and GI systems in various species. Larotrectinib had no adverse effect on haemodynamic parameters and ECG intervals in telemetered monkeys at exposures (C<sub>max</sub>) which are approximately 6‑fold the human therapeutic exposures. Larotrectinib had no neurobehavioural findings in adult animals (rats, mice, cynomolgus monkeys) at exposure (C<sub>max</sub>) at least 7‑fold higher than the human exposure. Larotrectinib had no effect on respiratory function in rats; at exposures (C<sub>max</sub>) at least 8‑times the human therapeutic exposure. In rats, larotrectinib accelerated intestinal transit and increased gastric secretion and acidity.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Purified water</p><p>Sucrose</p><p>Hydroxypropylbetadex</p><p>Glycerol (E&nbsp;422)</p><p>Sorbitol (E&nbsp;420)</p><p>Sodium citrate (E&nbsp;331)</p><p>Sodium dihydrogen phosphate dihydrate (E&nbsp;339)</p><p>Citric acid (E&nbsp;330)</p><p>Propylene glycol (E&nbsp;1520)</p><p>Potassium sorbate (E&nbsp;202)</p><p>Methyl parahydroxybenzoate (E&nbsp;218)</p><p>Citrus fruit flavour</p><p>Natural flavour</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0in; margin-right:0in; text-indent:0in">Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.

After first opening: 30 days.
Store in a refrigerator (2 °C - 8 °C).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&nbsp;&deg;C&nbsp;-&nbsp;8&nbsp;&deg;C).</p><p>Do not freeze.</p><p>&nbsp;</p><p>For storage conditions after first opening of the medicinal product, see section&nbsp;6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amber glass (type&nbsp;III) bottle with a child‑resistant polypropylene (PP) cap with a polyethylene (PE) seal liner.</p><p>&nbsp;</p><p>Each carton contains one bottle of 100&nbsp;mL oral solution.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Instructions for use:</u></p><p>&nbsp;</p><p><em>Oral syringe</em></p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Use a suitable oral syringe with CE&nbsp;marking and bottle adapter (28&nbsp;mm diameter) if applicable.</p><p style="margin-left:56.7pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&nbsp;&nbsp;&nbsp;&nbsp; For volumes less than 1&nbsp;mL use a 1&nbsp;mL oral syringe with 0.1&nbsp;mL graduation.</p><p style="margin-left:56.7pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&nbsp;&nbsp;&nbsp;&nbsp; For volumes of 1&nbsp;mL and higher use a 5&nbsp;mL oral syringe with 0.2&nbsp;mL graduation.</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Open the bottle: press the bottle cap and turn it counter clockwise.</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Insert the bottle adapter into the bottle neck and ensure it is well fixed.</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Take the oral syringe and ensure that the plunger is fully depressed. Put the oral syringe in the adapter opening. Turn the bottle upside down.</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Fill the oral syringe with small amount of solution by pulling the plunger down, then push the plunger upwards to remove any bubbles.</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Pull the plunger down to the graduation mark equal to the quantity in mL as prescribed.</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Turn the bottle the right way up and remove the oral syringe from the bottle adapter.</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Slowly depress the plunger, directing the liquid towards the inside cheek to allow for natural swallowing.</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Close the bottle with the original bottle cap (leaving the adapter in place).</p><p>&nbsp;</p><p><em>Nasogastric feeding tube</em></p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Use a suitable nasogastric feeding tube. The outer diameter of the nasogastric feeding tube should be selected based on the patient characteristics. Typical tube diameter, tube lengths and derived prime volumes are presented in Table&nbsp;7.</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The feeding should be stopped and the tube flushed with at least 10&nbsp;mL water. NOTE: See exceptions regarding neonates and patients with fluid restrictions in the sub‑point directly below.</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->A suitable syringe should be used to administer VITRAKVI to the nasogastric feeding tube.</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The tube should be flushed again with at least 10&nbsp;mL water to ensure VITRAKVI is delivered and to clear the tube.</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Neonates and children with fluid restrictions may require minimal flushing volume of 0.5&nbsp;to 1&nbsp;mL or flushing with air to deliver VITRAKVI.</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Restart the feeding.</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">Table&nbsp;7: Recommended tube dimensions per age group</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="vertical-align:top; width:63.8pt"><p><strong>Patient</strong></p></td><td style="vertical-align:top; width:106.3pt"><p style="text-align:center"><strong>Tube diameter for standard feeds</strong></p></td><td style="vertical-align:top; width:103.05pt"><p style="text-align:center"><strong>Tube diameter for high density feeds</strong></p></td><td style="vertical-align:top; width:92.9pt"><p style="text-align:center"><strong>Tube length (cm)</strong></p></td><td style="vertical-align:top; width:92.9pt"><p style="text-align:center"><strong>Tube prime volume (mL)</strong></p></td></tr><tr><td style="vertical-align:top; width:63.8pt"><p>Neonate</p></td><td style="vertical-align:top; width:106.3pt"><p style="margin-left:0in; margin-right:37.1pt; text-align:right">4‑5&nbsp;FR</p></td><td style="vertical-align:top; width:103.05pt"><p style="margin-left:0in; margin-right:33.85pt; text-align:right">6&nbsp;FR</p></td><td style="vertical-align:top; width:92.9pt"><p style="text-align:center">40‑50</p></td><td style="vertical-align:top; width:92.9pt"><p style="text-align:center">0.25‑0.5</p></td></tr><tr><td style="vertical-align:top; width:63.8pt"><p>Children</p></td><td style="vertical-align:top; width:106.3pt"><p style="margin-left:0in; margin-right:37.1pt; text-align:right">6&nbsp;FR</p></td><td style="vertical-align:top; width:103.05pt"><p style="margin-left:0in; margin-right:33.85pt; text-align:right">8&nbsp;FR</p></td><td style="vertical-align:top; width:92.9pt"><p style="text-align:center">50‑80</p></td><td style="vertical-align:top; width:92.9pt"><p style="text-align:center">0.7‑1.4</p></td></tr><tr><td style="vertical-align:top; width:63.8pt"><p>Adult</p></td><td style="vertical-align:top; width:106.3pt"><p style="margin-left:0in; margin-right:37.1pt; text-align:right">8&nbsp;FR</p></td><td style="vertical-align:top; width:103.05pt"><p style="margin-left:0in; margin-right:33.85pt; text-align:right">10&nbsp;FR</p></td><td style="vertical-align:top; width:92.9pt"><p style="text-align:center">80‑120</p></td><td style="vertical-align:top; width:92.9pt"><p style="text-align:center">1.4‑4.2</p></td></tr></tbody></table><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bayer AG
51368 Leverkusen
Germany

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>